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ABSTRACT 
 
Progress toward a Colon Targeting  
Nanoparticle Based Drug Delivery System. (May 2012) 
Xiao Yu, B.S., Tianjin University; 
M.Med., Zhejiang University 
Chair of Advisory Committee: Dr. Michael Pishko 
 
Hydrophobic drug paclitaxel nanoparticles (PAX NPs) and pH sensitive 
hydrogels were prepared in this study to build a colon targeting nanoparticle based drug 
delivery system for oral administration.  
Negative charged PAX NPs at the size of 110 ± 10 nm were fabricated, 
characterized and then encapsulated in synthetic / biomacromolecule shell chitosan, 
dextran-sulfate using a layer by layer (LbL) self-assembly technique. Surface 
modifications were performed by covalently conjugating with poly (ethylene glycol) 
(H2N-PEG-carboxymethyl, Mw 3400) and fluorescence labeled wheat germ agglutinin 
(F-WGA), so as to build a biocompatible and targeted drug delivery system. Extended 
release of drug paclitaxel can be realized by adding more polyelectrolyte layers in the 
shell. High cell viability with PEG conjugated and high binding capacities of WGA 
modified nanoparticles with Caco-2 cells were observed. Preliminary study on stability 
of the nanoparticles in suspension at different pH was also performed. 
Two dextran based pH sensitive and enzyme degradable hydrogels: dextran 
maleic acid (Dex-MA), and glycidyl methacrylated dextran (Dex-GMA) were 
synthesized for oral delivery of nanoparticles. Hydrogels of both kinds were stable in 
simulated gastric fluid, but were prone to swelling and degradation in the presence or 
absence of enzyme dextranase in simulated intestinal fluid. The release profiles of 
nanoparticles could be tuned from 5 hr to 24 hr periods of time with more than 85% of 
iv 
 
the nanoparticle released in the simulated intestinal fluid. The release of PAX NPs was 
completed with longer time periods (45 hr-120 hr). Two possible release mechanisms 
were discussed for Dex-MA and Dex-GMA-co-AA hydrogels respectively: degradation 
controlled, and diffusion controlled.  
These biodegradable hydrogels, which can release nanoparticles depending on 
pH changes, together with the biocompatible and targeted nanoparticles, may be suitable 
as a potential colon targeting system for oral delivery of drug nanoparticles.  
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NOMENCLATURE 
 
CS/DEX-PEG            Chitosan/dextran conjugated with PEG 
Dex-MA                     Dextran maleic acid 
Dex-GMA                  Glycidyl methacrylated dextran 
EDC                            1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide 
F-NPs Fluorescent nanoparticles 
F-WGA                       Fluorescence labeled wheat germ agglutinin  
LbL                             Layer by layer  
L.E. /E.E.                    Loading efficiency / encapsulation efficiency 
PAH                            Poly (allylamine) hydrochloride 
PAX NPs                    Paclitaxel nanoparticles 
PE                               Polyelectrolyte 
PEG                            Poly (ethylene glycol) (NH2-PEG-carboxymethyl) 
PEM                           Polyelectrolyte multilayer 
PSSCMA                    Poly (4-styrenesulfonic acid-co-maleic acid) sodium salt 
PS NPs                        Polystyrene nanoparticles 
PVA                            Poly (vinyl alcohol) 
SGF Simulated gastric fluid 
SIF Simulated intestinal fluid 
S-NHS                        Sulfo N-hydroxysulfosuccinimide 
SR                               Swelling ratio 
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1. INTRODUCTION 
 
1.1 Motivation  
Normal cell cycle consists of an ordered set of events, resulting in the production 
of two daughter cells. Cancer, known as medical neoplasm, is a broad group of various 
diseases, all involving unregulated cell growth. Cancer cells have defects in regulatory 
circuits that govern normal cell proliferation and homeostasis, which causes cells 
dividing and growing uncontrollably, forming malignant tumors, and invading nearby 
parts of the body.
1
 Observations of human cancers and animal models argue that tumor 
development proceeds via a process formally analogous to Darwinian evolution, in 
which a succession of genetic changes, each conferring one or another type of growth 
advantage, leads to the progressive conversion of normal human cells into cancer cells.
2
  
This year, cancer is projected to become the leading cause of death worldwide. Colon 
and rectum cancer, also known as colorectal cancer or large bowel cancer, was the third 
leading cause of cancer-related death in 2011.
3
  
Effective treatments of cancer include surgical removal, chemotherapy, 
radiotherapy, immunotherapy, and their combinations.
4
 Presently, the challenge of an 
effective anti-cancer treatment in the pharmaceutical industry has been more about the 
development of creative formulations, which are capable of providing access to the 
desired tissue, while maintaining prolonged therapeutic effects.
5
 For chemotherapy, 
delivery of the anticancer drugs to the desired site (drug targeting) and release of them in 
a prolonged profile (controlled release) will play a major role in the future.  
Oral drug delivery is the most popular route to treat all kinds of diseases. It has 
the advantages over current cancer chemotherapy. It is convenient and has higher 
 
 
____________ 
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patient compliance, especially for patients with advanced or metastatic cancer.
6
 
Challenges that exist in oral drug delivery include: low bioavailability (hydrophobic 
drug) and acidic environment in human stomach (disruption of the delivery vehicle).
4
 
However, with the development of nanotechnology and environmental stimuli smart 
materials, possible solutions and new improved chemotherapy may be provided.  
Paclitaxel (PAX, Figure 1) is one of the best anti-tumor drugs found from nature 
in the past decades. It is the first member of texane class and has unique ability to 
stabilize microtubule function, thus inducing cell death.
7
 Paclitaxel is water insoluble, 
and chemical solvents such as ethanol, Tween 80, and castor oil (Cremophor EL) are 
used in currently approved formulations. The commercially formulated paclitaxel is a 
mixture of Cremophor EL and dehydrated ethanol under the trademark 'TAXOL' 
(Bristol-Myers Squibb Co., NJ, USA). However, this formulation caused side effects 
including hypersensitivity reaction, thinned or brittle hair, pain in the joints of the arms 
or legs, fever, cough, which were associated with the Cremophor EL used. To avoid 
these solvent side effects, Cremophor EL-reduce or free formulations such as albumin-
bound nanoparticles, trademark 'Abraxane' (American Bioscience, Inc., CA, USA), 
mucoadhesive lipid dosage, lyophilized polymeric micelles (Genexol-PM, Samyang Co. 
Seoul, Korea) have been developed.
8, 9, 10
    
 
 
Figure 1. Chemical structure of paclitaxel; reproduced and cited.  
 
In this study, a novel lectin-mediated nanoparticle drug delivery system were 
fabricated, and polysaccharide-based delivery devices were designed and prepared, 
which can potentially target the human colon and maximize the therapeutic impact on 
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the pathologic cells. Poly (ethylene glycol) (PEG) and lectin F-WGA will be 
chemisorbed to the surface of the nanoshell, promoting biocompatibility and tumor 
specificity of the drug delivery system.  
 
1.2 Specific aims and based hypothesis  
1.2.1 Fabrication, encapsulation and surface modifications of paclitaxel based 
core-shell structured nanoparticles 
This anti-tumor drug delivery system consists of a drug based core encapsulated 
by polyelectrolyte layers including synthetic polymers Poly (4-styrenesulfonic acid-co-
maleic acid) sodium salt/Poly (allylamine) hydrochloride (PSSCMA/PAH), and 
biomacromolecules chitosan/dextran. The solid paclitaxel drug cores will be fabricated 
by a solvent-evaporation emulsification method. The core-shell structured nanospheres 
will be formed by the layer by layer (LbL) self-assembly technique and specific sites on 
the surfaces will be provided to enhance biocompatibility and cell targeting.   
 
1.2.2 Synthesis and characterization of new biocompatible and pH sensitive 
hydrogels for colon targeting drug delivery 
Synthesize biocompatible and pH sensitive dextran based hydrogels that can 
potentially deliver the nanoparticles to the human colon and degrade in the presence of 
the enzyme dextranase. These hydrogels can respond to the environmental pH changes. 
Enzymes produced by the micro flora in human colon can degrade the backbone of the 
hydrogels and then release the nanoparticles trapped inside. Hydrogels will be 
characterized based on the precursors’ degree of substitution, the hydrogel swelling 
ratios in different pH buffers (i.e. SIF vs. SGF), and ratios between two monomers, etc.  
 
1.2.3 In vitro nanoparticle and paclitaxel release studies 
F-NPs and PAX NPs will be loaded into different dextran based hydrogels. The 
release profiles can be determined by measuring the fluorescent level or drug 
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concentration versus time. Tunable release can be obtained by adjusting the hydrogel 
compositions and layer number of the self-assembly. 
 
1.2.4 In vitro study with Caco-2 cells  
This aims to test the efficiency of this drug delivery system. Nanoparticles will 
be encapsulated and modified before being incubated with Caco-2 cells to study the 
binding and uptake capability of the nanoparticles. Suspended Caco-2 cells will be used 
to study the biocompatibility of these dextran based hydrogels. 
The above proposed research aims are based on the following hypothesis: LbL 
self-assembled nanoparticles will be successfully fabricated due to the electrostatic 
interaction between cationic and anionic polyelectrolytes; the hydrogel will effectively 
protect the nanoparticles in the stomach, degrade and release them in the colon; 
controlled release of the drug can be achieved by tuning the non-degradable composition 
in the hydrogels, the number of polyelectrolyte layers and their layer thickness; particle 
surface modifications can minimize opsonization and target specifically to Caco-2 cells.  
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2. LITERATURE REVIEW 
 
 
2.1 Nanoparticle based drug delivery system 
2.1.1 Layer by layer (LbL) self-assembly  
As material science has been developed into an interdisciplinary field, organic, 
polymeric and even biological components, besides classic metals and inorganic 
compounds, have been integrated in the new material development for a variety of 
applications.
11
  
LbL self-assembly is such a technique that oppositely charged polymers can be 
deposited on solid surfaces at ambient conditions. (Figure 2) It provides a convenient 
and simple approach to fabricate multilayered polymer films at the nanoscale.
12
 It was 
popularized in 1992 by Decher and has been demonstrated as a general and reproducible 
technique to build up multi-component and functional nano-scale thin films on solid 
substrates.
13,11
 Sequential addition of the anionic and cationic polyelectrolytes is 
characterized by a stepwise increase of the adsorbed amount and layer thickness. It is 
also confirmed by the alternating positive and negative values from the zeta potential 
measurements.
14
 X-ray photoelectron spectroscopy (XPS) can further provide details of 
the surface chemistry of the polyelectrolyte multilayer.    
Electrostatic interaction between oppositely charged macromolecules is the main 
driving force of forming these nano thin films. For electrostatic interactions a certain 
number of ionic bonds between the layer and the substrate or between each adjacent 
layer are required for adherence.
11
  Stability of the multilayer of polyelectrolytes has 
been studied and several factors were considered to have pronounced effects: polymer 
charge, charge density, ionic strength, buffer pH (also influences polymer charge), and 
polymer type.
13
  Stable polyelectrolyte thin films can be formed when both polymers are 
highly charged and the ionic strength is low.
14
 The pH of the buffer would affect the 
degree of dissociation, charge state and conformation of the weak polyelectrolyte in the 
solution, e.g. chitosan. Nanoscale structure of these layers can therefore be tuned based 
6 
 
on pH changes.
13
 It was found that thicker polyelectrolyte layers PAH/PAA were 
obtained when the pH value of the PAA solution was close to its pKa at 4.5. Ionic 
strength in the deposition and washing solutions also increased the thickness of 
PAA/PAH coatings.
15
 
 
 
Figure 2. Schematic of the LbL procedure. 
 
Besides the electrostatic interactions, other secondary interactions, such as 
hydrogen bonding, hydrophobic interaction and van der Waals force, also exist.
16
 
Interactions between polyions had been considered in determining the selectivity of three 
basic polyamines, which depended on degree of ionization as caused by the pH in the 
solution, as well as the number of hydrogen bonding units, in the polyacid or on the 
surface.
16
 At low pH, the secondary interaction of polyacid polymer appeared to be 
particular important with heightened hydrogen bonding formation and maximized 
potential hydrophobic interaction.
16
 Both synthetic polymers and biomacromolecules 
have been successfully used for the deposition of multilayered polyelectrolytes.
13, 15
 
With the increased application of LbL self-assembly technique in the biomedical field, 
biomacromolecules have gained more and more attention. Biopolymers are a class of 
polymers produced by living organisms. Starch, proteins, peptides and DNA all belong 
to biopolymers. Biologically derived polysaccharide is one kind of the biopolymers and 
can be negatively or positively charged in solution under certain pH value, therefore they 
7 
 
can be used as polyelectrolytes for the LbL self-assembly. Due to their origin from 
nature, they are normally non-toxic, biocompatible and biodegradable.  
Chitosan (CS) is a natural polysaccharide usually obtained from chitin, and 
presently it is extensively used in pharmaceutical, cosmetics, and food industries.
17
 
Figure 3 (left) shows its structure. It has primary amines in the repeating units, with an 
intrinsic pKa varying from 6.46 to 7.32.
13
 Chitosan is a weak polycation, and usually 
insoluble above its pKa. After protonation of the amine group below its pKa, it becomes 
soluble and positively charged.
18
 Therefore it can act as a weak polycation in the diluted 
acid solution. Weak polyelectrolytes have a rich range of electrostatic and secondary 
interactions arising from their structures and degree of ionization. Fine control of 
building the polyelectrolyte layers may be realized by manipulating these interactions 
through proper solution conditions and polyelectrolyte structures.
16
 Changing the charge 
density and ionic strength in the solution can change the conformation of chitosan 
chains.
19
 The pH dependent thickness behavior of sequentially adsorbing this chitosan 
layer may be observed. Dramatically different polymer adsorption behavior was found 
as one systematically increases the charge density of a weak polyelectrolyte; thickness 
could change from 8 nm to 0.4 nm over a very narrow pH range.
20
 Various medical 
applications of chitosan as a polyelectrolyte layer in nanostructured thin films had been 
identified, such as sensing and biosensing.
21
 It can serve as a matrix for immobilization 
of biomolecules in the LbL films, helping preserve the bioactivity of biomolecules for 
long periods of time even in dry, solid films. Its biocompatibility properties may also 
facilitate the application for tissue engineering.
21
   
Dextran sulfate (Dex) in sodium salt form is a strong polyanion, soluble and 
stable in water with a broad range of pH values (Figure 3 right). It contains 
approximately 17% sulfur which is equivalent to approximately 2.3 sulfate groups per 
glucosyl residue. Due to the repulsion of the negatively charged sulfate groups, the 
dextran sulfate polymer will be fully extended in low ionic strength solutions.  As salt 
(increase of ionic strength) was added in the LbL assembly procedure, a thicker layer 
could be obtained with intact characteristics of each layer.
22
 The biodegradability of 
8 
 
these biomacromolecule thin films is a very important requirement for them to be used 
in biomedical fields. Enzyme hydrolysis of the chitosan and dextran LbL assembly had 
been quantitatively studied and it was found the construction of an LbL assembly 
facilitated rapid hydrolysis when the polymer substrate exhibited electrostatic repulsion 
against the enzyme. Controlled release of therapeutics can be therefore performed by 
adjusting the enzyme hydrolysis rate.
22
 LbL assembly of chitosan and dextran-sulfate 
polyelectrolytes could also have alternate anti- vs. pro-coagulant activity of human 
whole blood at the 1 M of NaCl buffer concentration.
23
 Another dextran based weak 
polyelectrolyte, carboxymethyl dextran sodium salt (CM-dextran), can also be used in 
this LbL self-assembly procedure. It can provide specific surface sites for functional 
modifications when adsorbed as the outmost layer. The pKa of this weak polyanion is at 
6.1; similar to chitosan, the pH of the solution needs to be adjusted for better 
encapsulation.  
 
                   
Figure 3. Chemical structures of chitosan (left) and dextran-sulfate sodium salt (right) 
18
. 
2.1.2 PEG conjugation onto drug nanoparticles 
Poly (ethylene glycol) (PEG) has been intensively studied recently in drug 
delivery, especially in the development of nanoparticle based formulation. Peptides and 
proteins can be encapsulated within the nanoparticles to increase their potential 
therapeutic effect.
24
 It was found that hydrophilic surfaces of the PLA-PEG conjugated 
nanoparticles could lead to extended nasal delivery of active antigen, and more efficient 
transport through rat nasal mucosa.
24
 Without PEG surface modifications, nanoparticles 
9 
 
can be quickly opsonized and cleared by the macrophages. So the PEG conjugation was 
developed as the first strategy to increase nanoparticles’ circulating time by avoiding 
non-specific protein adhesion on the particles’ surfaces in blood upon administration.25 
Moreover, the particle surface can be modified while still maintaining its main biological 
functions, such as enzyme activity or receptor recognition.
26
 It can also shield particles 
from the uptake by the reticuloendothelial system (RES), preventing recognition and 
degradation by proteolytic enzymes. The PEG conjugation increased the apparent size of 
the polypeptide, thus reducing the renal filtration and altering biodistribution.
27
  
 
2.1.3 Conjugation of fluorescent labeled wheat germ agglutinin (F-WGA)  
Transformed or cancerous cells often express different amount of glycans 
compared with their normal counterparts, thus providing a possible solution to deliver 
the drug particles specifically to tumor cells.
28
 Lectin is a sugar-binding protein that can 
recognize and bind to sugar complexes due to its high specificity for the chemical 
structure of the glycans. It has been proved that nanoparticles conjugated with lectin F-
WGA will allow efficiently targeting to cancer cells. Recently it has been demonstrated 
in vitro that it may be possible to exploit the increased WGA binding capacity exhibited 
by Caco-2 cells compared to that of non-cancerous human colonocytes for tumor-
specific drug delivery in colon cancer chemotherapy.
29
 The toxicity study of WGA 
conjugated nanoparticles was also investigated and it was demonstrated in vivo to be a 
safe carrier system for intranasal delivery of therapeutic agents to the brain.
30
  
 
2.1.4 Paclitaxel nanoparticle based formulation 
Paclitaxel is one of the best anti-cancer drugs found from nature and has been 
approved by the FDA for the treatment of breast cancer, ovarian cancer and non-small-
cell lung cancer.
31
 Commercially available paclitaxel formulations require the use of 
nonionic surfactant polyoxyethylated castor oil, i.e. Cremophor EL
®
 and ethanol, 
because of its poor aqueous solubility and oral bioavailability.
32
 However, the 
Cremophor EL can cause serious side effects including hypersensitivity reactions, 
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neurotoxicity, nephrotoxicity and hypotensive vasodilation.
33
 Therefore, novel 
Cremophor EL free formulations have been developed recently.  
Nanoparticle albumin-bound paclitaxel (nab™-paclitaxel) is a solvent-free 
paclitaxel formulation, which can be prepared by high-pressure homogenization of 
paclitaxel in the presence of albumin into a nanoparticle suspension.
31
 Paclitaxel 
nanoparticles (PAX NPs) at the size of 130 nm have several advantages over the 
Cremophor EL-paclitaxel: no need for premedication for the hypersensitivity reactions, 
shorter infusion time and elimination of Cremophor EL impact, etc.
31-32
 Phase I and 
pharmacokinetic study of this formulation had been performed.
32
 No acute 
hypersensitivity reactions were observed for all nineteen patients during the infusion 
period, and the maximum tolerated dose (MTD) was determined to be 300 mg/m
2
. These 
results supported further Phase II trials to finally determine the drug’s ant-tumor 
activity.
32
 
Another novel nanoparticle based system, consisting of chitosan and glyceryl 
monooleate (GMO), was also developed for sustained paclitaxel delivery.
33
 Polycationic 
nanoparticles (400 to 700 nm) were fabricated by the multiple emulsion solvent 
evaporation methods and showed a hydrophobic inner-core with a hydrophilic coating. 
This novel formulation exhibited a fourfold increase on cellular uptake and a 1000-fold 
reduction in the IC50 (half maximum inhibitory concentration) of paclitaxel.
33
 
A polymer cross-linking method was used to engineer paclitaxel-loaded 
hyaluronan nanoparticles for local delivery of the drug for cancer therapy.
34
 In vivo 
administration of the drug–loaded nanoparticles via direct intratumoral injection in 
female rats showed effective inhibition of tumor growth in all treated rats. One case of 
complete remission of the tumor nodule and two cases of persistent reduction of tumor 
size had also been observed on subsequent days.
34
 
The latest paclitaxel nanoparticle formulation PGG-PAX is based on poly-(ɤ-
glutamylglutamine) (PGG) and paclitaxel (PAX) being linked via ester bonds.
35
 Very 
small nanoparticls were formed spontaneously in plasma. Three different tumor models 
were used in the study and the PGG-PAX formulation produced greater inhibition of 
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tumor growth than Abraxane (the albumin-bound paclitaxel nanoparticle based 
formulation) among all the models when mice were given single equitoxic doses of the 
drug.
35
 
 
2.2 Oral and colon targeting drug delivery 
2.2.1 Colon targeting oral drug delivery  
Challenges that exist in oral drug delivery of paclitaxel include: low 
bioavailability due to the hydrophobic property of the drug itself, first metabolism 
process, acidic environment in human stomach, and possible leakage of the dosage when 
passing through the small intestine.
4
 However, combining nanotechnology and smart 
hydrogels, novel nanoparticle formulations together with site specific delivery vehicles 
show great potential in promoting new chemotherapy and provide possible solutions to 
these problems.  
Colon drug delivery has lots of advantages: near neutral pH environment, less 
enzyme activity and longer residence time, which could improve the drug 
bioavailability, reduce side effects and facilitate the site specific targeting .
36
  
Colon drug delivery can be realized by encapsulating active compounds or 
nanoparticles within proper delivery vehicles, which can help the therapeutics survive 
the severe environment in the human stomach, going through the small intestine within 
the residence time, and finally reach the colon and then degrade in the colon in the 
presence of specific enzymes. These hydrogels, also called smart materials, function 
because of a stimuli-responsive mechanism. Smart materials can change their structures 
reversibly in response to external change including pH, temperature, light, and 
concentration of chemical substances.
37
   
Physiological pH of human gastrointestinal tract (GIT) increases progressively 
from the stomach (pH 1-2), to small intestine (pH 6-7) at the site of digestion and to 7-8 
in the distal ileum.
38
 Due to these physiological characteristics, a controlled drug 
delivery system could be designed to potentially regulate the drug release through 
external pH changes. Moreover, the intestinal micro flora are characterized by a complex 
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and relatively stable community of microorganisms, some of which are responsible for a 
wide variety of metabolic processes, such as degradation of polysaccharides.
38
 Colon 
targeting drug delivery vehicles, pH sensitive hydrogels, combining properties of 
responding to physiological pH changes and enzyme induced decomposition in the 
human colon, may be potential good candidates for oral administration of nanoparticles. 
(Figure 4) Factors that may affect the enzymatic degradation include temperature, buffer 
pH, sugar type and the structure of the hydrogel network.
39
   
 
 
Figure 4. Colon targeting drug delivery for oral administration, reproduced with 
modification.
40
  
 
2.2.2 Polysaccharide based pH sensitive and biodegradable hydrogels 
The use of biodegradable polymers holds great promise among the different 
approaches to achieve colon targeting drug delivery. Natural polymers, e.g. 
polysaccharides, have great appeal as they are comprised of polymers with a large 
number of derivable groups, a wide range of molecular weights, varying chemical 
compositions, low toxicity and specific biodegradability.
41
  
Dextrans are a class of polysaccharides with a linear polymer backbone with 
mainly 1, 6-α-d-glucopyranosidic linkages. They are obtained from bacterial cultures 
of Leuconostoc mesenteroides NRRL B-512.
42
 To form a functional hydrogel, different 
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chemical modifications have been performed to synthesize suitable precursors.
43,44
 
Methacrylated dextran is one of the most popular photo-reactive derivatives that can be 
copolymerized to form pH sensitive hydrogels.
45
 At high derivation degree in 
methacrylic groups (20 mol %), the photocrosslinking can take place in aqueous solution 
in the absence of photoinitiators.
46
 Dextran-maleic acid is another precursor that can be 
synthesized by reacting dextran with maleic anhydride in the presence of a catalyst 
(Figure 5).
44
 It can be photocrosslinked with a well-known temperature sensitive 
precursor NIPAAm to form hybrid hydrogels that exhibit duo environmental responsive 
properties.
47
 Besides dextran, inulin is also a good natural polysaccharide that has been 
derived with methacrylic anhydride (MA), which forms inulin based hydrogel under UV 
irradiation without using photoinitiators.
48
 A further modified hydrogel inulin-MA-SA 
(succinic anhydride) is synthesized, exhibiting pH sensitive property and improved acid-
resisting ability.
48
   
 
 
Figure 5. Preparation of precursor dextran-maleic acid. Reproduced.
44
 
 
All the  polysaccharide based hydrogels can be degraded by enzyme 
polysaccharidases, like glycosidase, which are released by the human colonic 
microflora.
41
 Degradation rates of these hydrogels can be adjusted through changing the 
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degree of substitution when synthesizing the precursor, the cross-linking density during 
the UV irradiation, and copolymer component compositions, etc.  
 
2.3 In vitro drug release models 
In vitro dissolution study has been well recognized as an important element in the 
drug development. It is defined as the rate of mass transfer from a solid surface into the 
dissolution medium. Drug dissolution and release kinetics are influenced by drug 
solubility, drug polymorphic form, particles size, and crystallinity.
49
  
 
 
Figure 6. Drug dissolution from the solid surface to medium. Reproduced.
49
 
 
In this study, anti-cancer drug paclitaxel will be trapped into nanoparticles; 
nanoparticles will be encapsulated by multi-layers of polyelectrolyte thin films. 
Hydrogels will be synthesized and used as a vehicle to possibly deliver these surface 
modified nanoparticles through oral route. The study of the drug release mechanisms 
from different kinds of delivery systems can promote a better understanding of what 
happened; important goals such as controlling the therapeutics’ concentration over time 
and predicting a release profile can be realized. Based on the drug delivery system 
prepared, two main releases can be expected: the drug molecules’ release from the 
nanoparticles and the nanoparticles’ release from the hydrogels.  
For low water soluble drugs, the self-erosion of the matrix is usually the 
dominant release mechanism. Different assumptions / models have been proposed to 
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describe the drug release mechanism from solid particles to the bulk medium. Diffusion 
layer model assumes that the reaction at the solid/liquid interface is instantaneous 
forming a saturated solution in the static liquid film adjacent to the solid surface. The 
interfacial barrier model proposes that there is a high activation free energy barrier that 
has to be overcome before the solid can dissolve. A third model called Danckwert’s 
model is to assume that the new packets of solvent reach the interface by eddy diffusion 
randomly.
49
 
 
Table 1. Summary of in-vitro drug release characterization mathematics models 
49
 
Model  Formula  Comments  
Zero order M=M0+K0t Ideal model 
First order dM/dt=k(Ms-Mt) Log(cumulative%) drug vs. time 
Higuchi Mt=kH (t)
0.5
 Release based on diffusion 
Korsmeyer-Peppas   
  
      n indicates release mechanism 
 
Table 1 summarized several mathematic models that describe in vitro drug 
releases. Zero order release kinetics is referred as the process of constant drug release 
from a drug delivery device and it is considered as the ideal way of drug releasing from 
vehicles. First order release is to describe the rate changes of drug which depends first 
orderly on the concentration gradients.
49
 Higuchi model is another popular model that 
describes the release of a drug from an insoluble matrix as the square root of a time-
dependent process based on Fickian diffusion.  
For drug release from a polymeric system, the Korsmeyer-Peppas model can be 
used and actually expand the application of the Higuchi model to characterize different 
diffusion mechanisms. This model was described as fitting the first 60% of the drug 
release data in the exponential equation  
  
  
    .50 The n value is used to classify 
different release mechanisms for cylindrical shaped matrices.
49
 Influence of the device 
geometry on the release mechanism, showing that for pure Fickian release, the exponent 
n has a limiting value of 0.43 for spheres.
51
 A value of n in the range from 0.43 to 1.00 
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indicated non-Fickian transport. When it takes a value of 1, the drug release is 
independent of time, suggesting zero order release kinetics, known as case II transport. 
Other n values and their corresponding release mechanisms were listed in Table 2. The 
choice of the appropriate mathematical model, when elucidating drug release 
mechanism, strongly depends on the desired or required predictive ability and accuracy 
of the model.
51
 
 
Table 2. Exponent n of the power law and drug release mechanism from the 
polymeric controlled release system 
51
 
Exponent n Release mechanisms 
Thin film Cylinder  Sphere  
0.5 0.45 0.43 Fickian diffusion 
0.5 – 1.0 0.45 – 0.89   0.43 – 0.85  Anomalous transport 
1.0 0.89 0.85 Case II transport 
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3. FABRICATION AND SURFACE MODIFICATION OF PAX NPs* 
 
Paclitaxel nanoparticles (PAX NPs) were fabricated at the size around 100 nm by 
the modified emulsification evaporation method. Both synthetic polyelectrolyte and 
biomacromolecules dextran and chitosan were assembled onto polystyrene / PAX NPs 
using the LbL self-assembly technique. Surface modifications were then performed onto 
nanoparticles’ outmost layer by conjugating with poly (ethylene glycol) and wheat germ 
agglutinin, so as to build a biocompatible and targeting drug delivery system.
18
 
 
3.1  Introduction 
Efficacy of most therapeutic drugs treating cancer requires sufficient amount and 
specific targeting to tumor cells. With the application of nanotechnology, drugs can be 
prepared in the form of nanoparticles with particular size, promoting passive 
accumulation of active molecules to pathological areas.
52, 53
  
Different kinds of polyelectrolyte nanofilms have been used for the LbL self-
assembly procedure, including charged metal, dyes, nanoparticles, proteins, DNA and 
virus. Today it has become a standard method with applications ranging from optical, 
electrochemical materials, biomedical devices and drug delivery systems.
54
 Using the 
layer-by-layer assembly method, the hydrophobic property of the drug can be 
temporarily covered by synthetic or biological polyelectrolytes.
55
 Through simply 
selecting proper outermost layers, biocompatible and targeted functional groups can be 
further modified onto the nanoparticles’ surfaces.  
 
 
 
 
____________ 
*Parts of this section are reproduced with the permission of (Yu, X.; Pishko, M. V., 
Biomacromolecules 2011, 12 (9), 3205-3212.). Copyright (2011) American Chemical 
Society. 
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3.2 Materials and Methods 
Poly (allylamine) hydrochloride (PAH, Mw~70 000 g/mol), Poly(4-
styrenesulfonic acid-co-maleic acid) sodium salt (PSSCMA, Mw~20,000 g/mol), 
chitosan (low molecular weight), dextran-sulfate (average Mw > 500,000), poly (vinyl 
alcohol) (PVA, Mw 9000-12,000 g/mol and Mw 22,000 g/mol), sodium alginate (from 
brown algae, low viscosity) were purchased from Sigma-Aldrich, USA. Semisynthetic 
paclitaxel (from Taxus sp.), ≥ 97% was purchased from Sigma, USA.  NH2-poly 
(ethylene glycol) - carboxymethyl, Mw~ 3400, was purchased from Laysan Bio, Inc. 
USA. Fluorescence labeled wheat germ agglutinin (F-WGA) was purchased from 
Sigma, USA. EDC (ECDI; 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide, HCl), and 
s-NHS (sulfo N- hydroxysulfosuccinimide) were purchased from Fisher scientific, USA. 
Ultrapure water used for all experiments was obtained from a Millipore system with a 
specific resistance 18 MΩ/cm. Polyelectrolyte solutions were prepared in a 30 mM KCl 
solution or 0.15 M NaCl. Phosphate-buffered saline solution (PBS, pH 7.4) consisted of 
1.1 mM potassium phosphate monobasic, 3 mM sodium phosphate dibasic heptahydrate, 
and 0.15 M NaCl. 
Preparation and characterization of paclitaxel nanoparticles. Solvent 
emulsification evaporation method has widely been used to encapsulate hydrophobic 
drugs in polymeric matrices.
56
 PAX NPs were prepared by a modified method without 
adding polymers into the organic phase.
57
 The procedure of preparing these 
nanoparticles can be described as: 2% w/v PVA and 1% w/v sodium alginate were 
dissolved in ultrapure water and then emulsified at a constant speed using a homogenizer 
with twice volume paclitaxel/acetone solution under low heat. After emulsifying for 2 
hours, the collected drug nanoparticles were centrifuged, suspended and washed by PBS 
at pH 7.4. All particles were stored at 4 ºC for further use.  
Loading efficiency (L.E.) was calculated according to the mass change before 
and after the emulsification procedure.
 
The encapsulation efficiency (E.E.) was 
calculated based on the mass ratio between the entrapped and the initial fed paclitaxel 
during the preparation process (1). 60 µL of well-sonicated PAX NPs were centrifuged 
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down and dissolved in 1 mL mobile phase acetonitrile/H2O (7/3, v/v) by sonication. 
Samples were then filtered for HPLC analysis.  
PAX NPs E.E. % =
mg/mL) (1  Paclitaxel fedinitially  of Mass
NPs PAXin   edencapsulat Paclitaxel of Mass
 
    
(1) 
Particle size distribution. Particle size distribution of ultracentrifuge and 
filtered particles was analyzed by Brookhaven ZetaPALS instrument with the dynamic 
light scattering (DLS) software and confirmed with results from SEM. Refractive index 
of the solution for all samples was set to 1.46.  
Layer by layer (LbL) assembly. LbL assembly is a technique that can be used 
to build multi-component polymer films in nanometer size onto solid substrates with 
controlled thickness and layer number.
11
 Alternating polyelectrolyte layers at the 
concentration of 20 mg/mL for PAH/PSSCMA (in 30 mM KCl), or 2 mg/mL for 
CS/DEX were adsorbed onto solid drug nanoparticles until a desired layer number was 
obtained. CS/DEX were prepared in 0.15 M NaCl; pH of the CS solution was adjusted to 
4.0, incubation time 20 min, and followed by ultracentrifugation at 11,000 rpm/20 min. 
(PAH/PSSCMA stands for a bilayer of PAH and PSSCMA; CS/DEX stands for a bilayer 
of chitosan and dextran adsorbed on particles).  
PEG and F-WGA surface modifications. After a desired number of 
polyelectrolyte layers were assembled onto PAX NPs, PEG and F-WGA were 
conjugated onto the particles by a standard carbodiimide chemical reaction.
58
 40 mg/mL 
of EDC was used as the carbodiimide and 4 mg/mL of s-NHS was added to activate and 
form a more stable intermediate first. Samples were shaken for 20 min at a speed of 500 
rpm, and then a twice-washing step was followed with 0.15 M NaCl. 10 mg of NH2-
PEG-CM / F-WGA was added to start the reaction for 20 hr at a speed of 500 rpm. 
Samples were washed three times after the reaction stopped. 
Surface characterization. X-ray photoelectron spectroscopy (XPS) analysis was 
performed using a Kratos Axis Ultra imaging XPS instrument to detect the variations in 
chemical composition and the oxidation state on particles’ surfaces. The X-ray source 
was a monochromatic aluminum (1486.6 eV). Survey and high resolution spectra were 
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collected at a takeoff angle of 90° with respect to the sample plane. 40 µL sample 
solution was dropped on small glass pieces and dried under ambient condition overnight. 
Charge neutralization was used. All spectra were referenced for C-C in the carbon 1s 
peak at 285 eV. Survey spectra were collected from 1200 to 0 eV with pass energy 160 
eV, and high resolution spectra (C 1s, O 1s, N 1s, and S 2p) were collected with pass 
energy 40 eV.  
Field emission-scanning electron microscopy (FE-SEM). JEOL JSM-7500F 
field emission scanning electron microscopy was used for particle imaging. All samples 
were prepared by dropping well sonicated and suspended drug nanoparticles onto a TEM 
copper grid, dried under ambient conditions and stored in a vacuum oven at room 
temperature for a day before imaging.  
 
3.3 Results 
3.3.1 Fabrication and characterization of PAX NPs   
3.3.1.1 Optimization of particles’ size and surface charges  
Most methods preparing nanoparticles involve a two-step reaction, preparation of 
an emulsified system and formation of nanoparticles. This second step is achieved either 
by the precipitation or the gelation of a polymer or by polymerization of monomers. 
Generally, the principle of second step gives its name to the method. Some other 
methods do not require the preparation of an emulsion prior to obtaining of the 
nanoparticles. They are based on the precipitation of spontaneous dispersed polymers or 
self-assembly of macromolecules to form nanogel or polyelectrolyte complex.
59
 Here we 
used a modified solvent emulsification evaporation method to prepare PAX NPs. 
PVA at two different molecular weights was used as the surfactant to study its 
effects on size and charge of the nanoparticles. (Table 3) These particles’ negative 
charge was possibly caused by the adsorption of sodium alginate. It is known that the 
emulsifier tends to bind to the nanoparticles surface through hydrophobic interactions, 
while the hydrophilic chains protrude into the surrounding medium, thus the negative 
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surface charges are present on the nanoparticles.
60
 Results of ζ-potential suggested 
organic/aqueous (O/W) phase ratio did not significantly affect particle’s ζ-potential. 
Final experimental condition to prepare PAX NPs was optimized to be: organic/aqueous 
phase ratio 2:1, PVA 9,000-10,000 g/mol. This condition resulted in the formation of 
solid drug nanoparticles at the average size of 110 nm, with a narrow size distribution 
and relative high ζ-potential of -40 ± 3.0 mV. These results confirmed that by varying 
experimental conditions, such as organic/aqueous phase ratio or organic phase 
composition, control of PAX NPs’ size and surface charge may be realized.60  
Size, morphology and surface charge of PAX NPs were characterized. Particle 
size determined by SEM was around 100 nm. The PAX NPs prepared by this method 
were within the tumor pore cutoff size 380-780 nm and negatively charged.
61
 The 
average L.E. for PAX NPs during the preparation process was 97.5%. Size distribution 
by SEM was obtained through counting the particle number at a specific size and then 
combining results of different areas from the SEM images. Figure 7 shows the data 
obtained by DLS, it resulted in 60 nm bigger of the average size as compared to the 
SEM results. This was possibly due to the different states of the particles, i.e. samples 
for SEM imaging were dried in a vacuum oven, while particles for DLS were well 
dispersed in an aqueous solution with the hydrodynamic diameter measured.  
 
Table 3. Optimized conditions for preparing PAX solid core nanoparticles 
Experiment 
Number 
a
 
O/W  
(v/v) 
PVA M.W. 
(g/mol) 
Size (nm)  
(SEM images) 
ζ-potential (mV) 
1 1:1 9,000-10,000 64 ± 20 -52 ± 3.0 
2 2:1 22,000 71 ± 10 -21 ± 6.4 
3 2:1 9,000-10,000 113 ± 14 -42 ± 2.6 
4 3:1 9,000-10,000 147 ± 28 -42 ± 2.1 
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Figure 7. Size distribution of PAX NPs by DLS. 
a
 
a
 Experiments were performed with the homogenization speed at 6000 rpm and organic 
phase composition at 2 mg paclitaxel/ 50 mL acetone. 2% w/v of PVA was dissolved in 
the aqueous phase. 
 
3.3.1.2 Encapsulation efficiency and stability of PAX NPs in different pH of the aqueous 
solutions  
PAX NPs were characterized by size and zeta potential as shown in Table 4. pH 
of the aqueous solution changes the charge state of alginate, thus it may influence the 
emulsification process and formation of PAX NPs.  
The pKa of alginate is 3.36-3.65 at 25 ºC. When the pH in the aqueous was 
adjusted below 3, alginate was precipitated as semi-transparent gels. When the pH 
changed to 3.6, after the emulsification and centrifugation, white precipitates were 
observed, which were difficult to dissolve in water. Transparent gels were formed during 
the washing of PAX NPs at this pH value. At pH 5 and 7.3, PAX NPs were well 
prepared with no gels formed. As the alginate chain would keep a greater part of ionized 
carboxyl groups at pH 5, more stable particle suspensions could be expected. 
Encapsulation efficiency was also higher when the aqueous pH was adjusted to 5.  
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Stability of PAX NPs in SGF/SIF/water (SGF: simulated gastric fluid; SIF: 
simulated intestinal fluid) was investigated. Measurement of zeta potential is one simple 
way to study the stability of a particle suspension. Charges of PAX NPs in water were 
caused by the carboxyl groups in alginate, which was adsorbed on the drug particles 
during the emulsification. The pH of the medium had a significant influence on 
particles’ surface charges. In SGF (pH 1.2), low charge on particle surfaces may induce 
instability and particle aggregation, as shown by zeta potential at -1 mV in KCl at pH 
1.2. The PAX NPs were stable in SIF and water, showing zeta potential around -40 or -
50 mV. (Table 5) Encapsulation efficiency did not change much between the medium 
SGF or SIF and the control (water).  
 
Table 4. Effect of pH in the aqueous solution on PAX NPs’ encapsulation efficiency 
 
pH  
of aqueous solution 
Particle size 
(DLS, nm) 
ζ-potential*    
(mV) 
Encapsulation 
Efficiency  (E.E.) % 
7.3 186 -39 ± 4.0 33 ± 1.6 
5 132 -50 ± 2.7 43 ± 2.0 
3.6 139 -31 ± 3.6 29 ± 7.1 
2 N/A N/A N/A 
 
*Zeta potential was measured in 1mM KCl at pH 5.6, room temperature. 
E.E. % was determined by [(measured PAX mass) / (initially fed PAX mass)] ×100 (n = 
3 for each experiment at given pH of aqueous solution). 
 
 
Table 5. Preliminary study on PAX NPs’ stability in SGF vs. SIF 
 
Measurement Control 
(water, pH 5.6) 
SGF  SIF  
Zeta potential*
 
Before incubation 
-50 ± 2.7 -28 ± 2.2 -39 ± 1.1 
Zeta Potential  
After incubation 
-39 ± 3.8 -16 ± 3.7 -50 ± 4.2 
Stability after incubation
†
 1 0.99 1.13 
 
† 
Stability was calculated by [paclitaxel concentration in PAX NPs incubated in SGF or 
SIF/ paclitaxel concentration in PAX NPs incubated in water]. Stability study was done 
in SGF/SIF/water in a shaking water bath for 2 hr at 37 ºC. 
* Zeta potential was measured in 1mM KCl at pH 5.6, room temperature. 
^ SGF: simulated gastric fluid; SIF: simulated intestinal fluid. 
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3.3.2 LbL  self-assembly with synthetic polymers and biomacromolecules 
 
Core-shell PAX NPs were fabricated via the LbL assembly technique. Solid PAX 
NPs with negative charge were used as the core and encapsulated by both synthetic and 
biocompatible polyelectrolytes (PEs). Ζ-potential of the sample was then measured 
(Figure 8). Synthetic polymers PAH/PSSCMA were well studied and the adsorption of 
these PEs alternatively onto PAX NPs suggested the feasibility of fabricating core-shell 
structured nanoparticles using the LbL technique.
57
 The outermost layer of these 
particles was set to be PSSCMA in order to provide the carboxylic acid group for surface 
modifications. 
  
 
Figure 8. Zeta potential of LbL polyelectrolyte assembled PAX NPs. 
 
Multilayer thin film in nanometer size was adsorbed onto solid drug 
nanoparticles mainly due to the electrostatic interaction between oppositely charged 
PEs.
62-63
 The nanoshell thickness built in this way could range from several to hundred 
nanometers by varying the layer number and layer thickness.
64
 Therefore, nanoscale 
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control on nanoparticles’ surface could be realized through tuning layer number and 
thickness. The effects of the solution’s ionic strength and pH on polyelectrolyte 
multilayer thickness had been studied, and it was found that the thickness would increase 
from less than 2 nm to 4 nm per bilayer by changing the solution’s pH. Using moderate 
ionic strength of buffer solutions could get access to wider ranges of layer thickness.
13
 
Besides the dominant electrostatic interaction between the PE layers, secondary 
interactions such as hydrogen bonding, van der Waals force, and hydrophobic force also 
exist. The effect of the solution’s pH on selective adsorption of PEs was investigated and 
showed that hydrogen bonding interaction of PAA became important at a low pH value, 
while electrostatic interactions became predominant at a high pH value. 
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From the chemical structures of PE pairs PAH/PSSCMA, CS/DEX, each PE 
layer has its own characteristic element. Cationic polymers PAH and CS have the 
element nitrogen; anionic polymers PSSCMA and DEX have the characteristic element 
sulfur. This fact provided us another way to confirm if the LbL assembly was successful. 
Figure 8 shows the high resolution N 1s XPS spectra during adsorption of synthetic 
polymers PAH/PSSCMA. High resolution XPS spectra could provide us additional 
information about surface sensitivity, since the atomic charge state could be resolved 
more detailed at a lower energy.
62
  Binding energy at 401 eV for N 1s represents 
protonated amine, which exists in PAH. From Figure 8, nitrogen intensity increased after 
adding PAH layer and decreased after adding PSSCMA layer. The initial N 1s peak 
failed to show up in the PAX NPs. This may be possible due to the fact that the 
paclitaxel is water insoluble and tends to stay inside of the nanoparticles, rather than on 
the surface of the nanoparticles when they were formed.
4
 High resolution S 2p XPS 
spectra also showed the increase of the peak intensity corresponding to the adsorbed 
PSSCMA layer.  
Relative atomic mass compositions could be obtained according to relative peak 
area integrated from XPS spectra. The atomic mass compositions of S and N changed in 
response with the adsorption of each PE layer, CS or DEX (Figure 10). Carbon and 
oxygen were two main elements existing on particle surfaces; N and S were two 
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characteristic elements presented on adsorbed PE layers. Alternating mass composition 
change of N and S suggested the successful adsorption of each PE layer. 
 
 
 
Figure 9. High resolution N 1s XPS spectra of PAH/PSSCMA LbL assembled onto 
PAX NPs.  (XPS samples were prepared by dropping 20 µL of well dispersed particle 
solutions onto glass chips and dried at ambient conditions overnight. XPS spectra were 
obtained after encapsulating each P.E. layer.) 
 
 
 
Figure 10. Atomic N and S mass composition change corresponding to alternative 
CS/DEX layer adsorbed onto PAX-NP. (1-bare PAX NPs; 2/4-add CS layer; 3/5-add 
DEX layer). 
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3.3.3 Surface modifications of core-shell nanoparticles  
3.3.3.1 Conjugation of Poly (ethylene glycol)  
After the polyelectrolyte layers were assembled onto nanoparticles, PEG (H2N-
PEG-CM, MW 3400) was conjugated to create a hydrophilic and biocompatible surface 
by a standard carbodiimide chemical reaction.
58
 High resolution C 1s, N 1s, S 2p XPS 
spectra were obtained and atomic state changes before and after the PEG chemisorptions 
were studied. In high resolution C 1s XPS spectra, there were two peaks presented 
before and after the PEG conjugation. Binding energy at 285 eV was referred as the C-C 
bond. There was a shoulder peak at 286.1 eV representing C-O or C-N bonds.
65
 After 
the PEG conjugation, an amide bond was formed and thus increased the intensity of the 
shoulder peak at 286.1 eV and decreased the intensity of the C-C peak at 285 eV, 
indicating the successful chemisorptions of PEG (Figure 11 a, b). 
High resolution N 1s XPS spectra showed there were two N 1s peaks at different 
binding energies (401 and 399 eV) before and after the PEG conjugation; this related to 
two different states of nitrogen.
62
 The percentage of relative peak area for the secondary 
amine at 399 eV increased from 48.5 % to 72.9 % after the PEG conjugation, which was 
due to the newly formed amide bond. After PEG conjugation with the outermost layer 
PSSCMA, high resolution S 2p XPS spectra showed the sulfur peak disappeared, 
suggesting that the outermost PSSCMA layer was fully covered by PEG. 
In order to conjugate CS/DEX encapsulated nanoparticles with PEG, the 
outermost layer of the nano-assembly was set to be PSSCMA. The carboxyl group in 
PSSCMA could react with the free amine group of H2N-PEG-CM, forming an amide 
bond. Figure 11-b showed the high resolution C 1s XPS peak spectra before and after 
the PEG conjugation. Similar to previous results, there was an obvious increase of 
intensity in C-N shoulder peak at the binding energy 286.3 eV, and the intensity of C-C 
bond at the binding energy 285 eV decreased after the PEG conjugation.  
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a) Synthetic polyelectrolyte PAH/PSSCMA 
 
b) Bio-polyelectrolyte CS/DEX 
Figure 11. High resolution C 1s XPS spectra of LbL assembled PAX NPs before and 
after PEG conjugation (both samples were encapsulated with 3 bilayers PEs). Binding 
energy at 285 eV represented carbon bond, and binding energy at 286-287 eV attributed 
to C-N or C-O bond. 
 
The predominant N 1s XPS peak switched from binding energy at 401 eV (free 
amine) to the peak at 399 eV (secondary amine) after the PEG modification (Table 6). 
No enhancement on N 1s peak intensity was observed after the conjugation, possibly 
because the amine group is not present in PEG repeat units. The PEG conjugation 
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shielded the last layer of DEX (containing sulfate groups), so the high resolution sulfur 
peak disappeared after conjugating with PEG (Figure 12). 
 
Table 6. High resolution N 1s XPS spectra analysis 
 B.E.(eV)  Area  Area%  
Before conjugation 399 0 0 
401 323 100 
After conjugation  399 255 80 
401 63 20 
 
 
Figure 12. High resolution S 2p XPS spectra before and after PEG modification. (Before 
PEG - PAX NPs encapsulated with 3 bilayers CS/DEX polyelectrolyte; after PEG- PAX 
NPs with 3 bilayers CS/DEX in conjugation with H2N-PEG-COOH). 
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  a) 
  b) 
Figure 13. SEM images of polyelectrolytes encapsulated PAX NPs. a) PAX-NP with 2 
bilayers of PAH/PSSCMA conjugated with PEG; b) PAX-NP with 2 bilayers of 
CS/DEX conjugated with PEG. Fresh prepared samples were well sonicated to break 
down possible aggregates. 10 µL of the suspended nanoparticles were dropped onto a 
TEM grid and dried at ambient conditions. All samples were stored in vacuum oven one 
day before imaging (room temperature).   
 
Figure 13 showed SEM images of 2 bilayers of PAH/PSSCMA and CS/DEX 
polyelectrolytes encapsulated PAX NPs. Samples were well dispersed by sonication to 
avoid aggregates, dropped onto a TEM grid and dried in a vacuum oven (room 
temperature). After PEG conjugation, particles were easily suspended and zeta potential 
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showed a value around -28 mV (with less than 5 % standard deviation), indicating highly 
charged particle surfaces, and therefore fairly stable particle dispersion. PEG with the 
good hydrophilic property and flexible chains in the solution could promote the 
repulsion effect between particles. It was found that the functions of PEG were to 
stabilize particles when covalently modified onto their surfaces and to reduce 
nonspecific protein adhesion.
66
  
 
3.3.3.2 Modification with F-WGA  
An effective antitumor drug therapy must be able to make its way into the blood 
vessels of the tumor, across the vessel wall, and finally migrate through the 
interstitium.
67
 Thus a tumor targeting system is necessary to deliver the reactive agent 
efficiently. Lectin is a protein that can recognize and bind to sugar complexes due to its 
high specificity for the chemical structure of the glycans. Transformed or cancerous cells 
often express different amounts of glycans compared with their normal counterparts.
68
 It 
has been proved that PAX NPs, which were conjugated with the lectin WGA, allowed 
efficient targeting to cancer cells.
28,69,70
 Fluorescence labeled WGA was used as the 
targeting moiety, and polystyrene sulfate nanoparticles were used as the model core in 
this experiment to study the feasibility of conjugating this lectin onto nanoparticle 
surfaces. 
First, the time of incubating the PAH/PSSCMA assembled particles with F-WGA 
was optimized. (Figure 14) Negative control suggested nonspecific adhesion of 
fluorescence lectin onto LbL assembled PAX NPs. It was increased as the exposing time 
to F-WGA was extended. There was no obvious difference between the blank samples 
and negative controls when incubating the particles with F-WGA for 20 min and 2 h. 
The fluorescence intensity of tagged particles reacted with F-WGA for 20 h had been 
increased significantly as compared to those reacted for shorter times. Tagged 
nanoparticles (20 h reaction) showed an almost seven fold increase in fluorescence 
intensity over its negative control sample, suggesting conjugation of this lectin onto the 
particles was successful. 
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Figure 14. Effect of reaction time on fluorescence intensity of F-WGA conjugated LbL 
assembled nanoparticles. 
b
 
b 
Blank: control, particles treated with the LbL procedure (P.E.:PAH/PSSCMA). 
Negative control: LbL self-assembled nanoparticles exposed to F-WGA but not EDAC. 
Tagged particles: LbL self-assembled nanoparticles conjugated with F-WGA using 
reagents EDAC and s-NHS. (All samples were treated with PEs: PAH/PSSCMA 5 
bilayers). 
 
After conjugating F-WGA onto LbL assembled nanoparticles, the wavelength of 
maximum fluorescence intensity shifted. Tagged particles showed the highest level of 
fluorescence intensity within the emission scanning range (Figure 15).  
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Figure 15. Fluorescence level of Bio-PEs encapsulated PS NPs and PAX NPs (3 
bilayers) in conjugation with F-WGA. Fluorescence intensity corresponding to F-WGA 
concentration indicated lectin F-WGA successfully conjugated onto nanoparticles’ 
surfaces. 
 
3.4 Conclusion 
A nanoparticle based system consisting of a paclitaxel drug based core 
encapsulated with a nanometer thick synthetic / biomacromolecule shell using the LbL 
assembly technique was successfully fabricated and characterized. The nanoshell 
provided reactive groups on the surface which could be further modified with functional 
moieties such as the hydrophilic polymer PEG and ligand to build a biocompatible and 
tumor specific targeting system. The thickness and density of the shell could be varied 
by controlling the experimental conditions, such as buffer pH, ionic strength (salt 
concentration), and polyelectrolyte composition.
7
 This biocompatible drug delivery 
system, which combined the EPR effect with active targeting property, might possibly 
provide an alternative to more efficiently deliver hydrophobic drugs to tumors, as 
compared to our previous work. 
57
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4. IN VITRO STUDY OF PACLITAXEL RELEASE FROM NANOPARTICLES*  
 
Core shell structured PAX NPs were prepared by encapsulating 
biomacromolecules chitosan and dextran using the LbL self-assembly technique. The 
poly (ethylene glycol) was conjugated onto the outermost layer of the drug nanoparticles 
for this release study. Adjustable release profiles may be obtained by tuning the layer 
number and buffer ionic strength.
18
 
 
4.1 Introduction 
For different types of cancer, (e.g. undetectable cancer, metastatic cancer, or 
cancer that is not confined in a solid tumor, etc), chemotherapy has been proved to be a 
necessary and effective treatment.
4
 However, for most anti-cancer drugs, the poor 
solubility causes low bioavailability, and the properties of the drugs themselves are 
usually unfavorable. Therefore, novel engineering formulations for increasing cellular 
uptake and cell targeting were developed, and drug release profiles from these delivery 
systems were studied.
4, 71
  
Nanoparticles made of biodegradable polymer poly(lactic-co-glycolic acid) 
(PLGA) is one promising system that may promote a controlled and targeted delivery of 
the drug with desired released kinetics, high cell uptake and high cytotoxicity.
4
 Poorly 
soluble drugs can also be incorporated in the inner core of a micelle system by physical 
entrapment through hydrophobic interaction between the drug and the copolymers.
72
   
 
 
 
___________ 
*Parts of this section are reproduced with the permission of (Yu, X.; Pishko, M. V., 
Biomacromolecules 2011, 12 (9), 3205-3212.). Copyright (2011) American Chemical 
Society. 
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In vitro study of the paclitaxel release from nanoparticles could be conducted by 
suspending the nanoparticles in buffer solution (pH 7.4) and then placing them in a tube 
in the shaking water bath, which was maintained at 37 ºC. Samples were withdrawn at 
particular time intervals by centrifuging down the nanoparticles and extracted the 
supernatant with dichloromethane (DCM), which were analyzed later by HPLC. The 
nanoparticle residuals were re-suspended by fresh buffer, and the release study 
continued. Another way to perform the in vitro release study is to prepare the same 
paclitaxel nanoparticle suspension and dilute it with PBS in a pre-calculated number of 
flasks. Two flasks were withdrawn at predetermined intervals to identify the paclitaxel 
concentration in the nanoparticle residuals. The release part can then be calculated based 
on the difference between the initial paclitaxel mass amount and the paclitaxel in the 
residuals. 
60
 
The surfaces of PAX NPs were observed containing micro-caves and pores rather 
than being simply smooth.
4
 This porous structure may be the reason paclitaxel can be 
released through diffusion. One possible mechanism could be: an initial burst release 
during the first 24 hr, followed by a slower and continuous diffusion release.
4, 60
  
So far there were few references studying the paclitaxel release from LbL self-
assembly. Core-shell structured PAX NPs were formed by encapsulating polyelectrolyte 
layers onto the PAX NPs. The release of the drug from the self-assembly is related to the 
stability of the system, the interaction between the hydrophobic drug and the amphiphilic 
matrix. The process may be explained as follows: as the environmental condition 
changes, the LbL structure is disrupted. Foreign buffer diffuses in, which causes the 
erosion of the core nanoparticles, and then the diffusion of the drug out of the matrix 
started.  
Paclitaxel and other taxanes have complex structures including the presence of 
numerous hydrolytically sensitive ester groups and a chiral center that readily undergoes 
epimerization. Degradation kinetics of paclitaxel have been intensively studied as a 
function of temperature, pH and buffer concentration, and degradation products were 
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identified by LC/MS.
73-74
 This phenomena should be noticed during the in vitro release 
studies.  
Synthetic polymers PAH/PSSCMA have been widely used as an example for 
microcapsule application and the layer permeability could be tuned to achieve controlled 
release of small molecules.
75
 However, for further application, bio-polyelectrolytes are 
preferred because they are biodegradable and biocompatible. In this experiment, PAX 
NPs were encapsulated within bio PE nanofilms, and the release profiles of paclitaxel 
from LbL assembly with different layer numbers were investigated.  
 
4.2 Materials and methods  
Chitosan (low molecular weight), dextran-sulfate (average Mw > 500,000), poly 
(vinyl alcohol) (PVA, Mw 9000-12,000 g/mol and Mw 22,000 g/mol), sodium alginate 
(from brown algae, low viscosity) were purchased from Sigma-Aldrich, USA. 
Semisynthetic paclitaxel (from Taxus sp.), ≥ 97% was purchased from Sigma.  Poly 
(ethylene glycol) (NH2-PEG-Carboxymethyl, Mw~ 3400) was purchased from Laysan 
Bio, Inc. USA. EDC (ECDI; 1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide, HCl), 
and s-NHS (Sulfo N-Hydroxysulfosuccinimide) were purchased from Fisher scientific, 
USA. Ultrapure water used for all experiments was obtained from a Millipore system 
with a specific resistance 18 MΩ/cm. Polyelectrolyte solutions were prepared in a 30 
mM KCl solution or 0.15 M NaCl. Phosphate-buffered saline solution (PBS, pH 7.4) 
consisted of 1.1 mM potassium phosphate monobasic, 3 mM sodium phosphate dibasic 
heptahydrate, and 0.15 M NaCl. 
Paclitaxel release from LbL assembly. The release profile of hydrophobic drug 
paclitaxel from LbL assembled core-shell nanoparticles was investigated. Studies were 
performed at the physiological pH condition in phosphate buffered saline solution (10 % 
DMSO) with magnetic stirring all the time. All 10 mL samples were withdrawn, and 
particles were ultracentrifuged down at a speed of 10,000 rpm/15 min. Supernatant was 
collected for further HPLC analysis, and particles were re-suspended by 10 mL of fresh 
PBS (10 % DMSO). Cumulative paclitaxel release as measured by HPLC was quantified 
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with time. The paclitaxel HPLC peak was integrated to calculate the area, with 
concentrations determined from the calibration curve. 
High performance liquid chromatography (HPLC). The paclitaxel 
concentration was analyzed using Waters Breeze HPLC System with a refractive index 
detector. The drug release was monitored at predetermined times. The supernatant was 
extracted by dichloromethane (DCM) three times. DCM phase was then evaporated at 
low heat under air flow overnight until fully dried. The residue was then dissolved in the 
mobile phase of acetonitrile: water (70:30, v/v), and analyzed by HPLC at a flow rate of 
1 mL/min, injection volume of 20 µL using a reverse phase column C 18 (Higgins 
Analytical, Inc., PROTO 200 C18 column 5 µm, 250 × 4.6 mm, CA, U.S.A.). Column 
temperature was set to 30 ºC, and the detector temperature was maintained at 35 ºC. This 
HPLC technique was analytically validated.
76
 For all release studies, 10 % v/v DMSO 
was added to avoid paclitaxel saturation in the aqueous solution.
77
 All HPLC 
measurements were at least duplicated with three parallel samples each time. A 
calibration curve was obtained by preparing standard paclitaxel (≥ 97%) solutions at 
different concentrations. The calibration concentration ranges from 5 µg/mL to 100 
µg/mL.   
 
4.3 Results  
4.3.1 Fabrication of LbL assembled nanoparticles 
PAX NPs were prepared by a modified emulsification evaporation method. The 
particle size was around 120-130 nm, and zeta potential was at -41 eV. The chitosan and 
dextran were encapsulated onto the PAX NPs alternatively until the desired layer 
number was obtained. To stabilize the nanoparticles in suspension, PEG was modified at 
last and the particles were ended up with a zeta potential at -32 eV. These PEG 
conjugated PAX NPs were then stored in 4 ºC fridge for further use. All release 
experiments were performed with fresh prepared PAX NPs (prepared within 3 days 
before use).  
38 
 
 
 
 
Figure 16. Zeta potential of chitosan and dextran encapsulated PAX NPs. 
 
4.3.2 Release of paclitaxel from nanoparticles 
4.3.2.1 HPLC calibration curve 
Since a refractive index detector was used through the whole release studies. The 
calibration curve between paclitaxel concentration in standard samples and HPLC 
integrated area was obtained to validate the assay. Paclitaxel concentrations ranging 
from 5 µg/mL to 100 µg/mL were prepared and analyzed by HPLC. Retention time for 
the standard samples ranges from (4.432 ± 0.008) min to (4.648 ± 0.059) min. This may 
be caused by the degradation of paclitaxel in the aqueous solution over time.
73
 So both 
standard and the test samples should be prepared and kept as fresh as possible for HPLC 
analysis, i.e. within 3 days after acquirement. 
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Figure 17. HPLC calibration curves of standard paclitaxel. Note: HPLC calibration 
curve should be measured every time before the experimental samples are analyzed.  
 
4.3.2.2 SEM images of PAX NPs 
 
Figure 18. SEM images of bare PAX NPs (above two) and polyelectrolytes 
encapsulated PAX NPs (Figure 13). Fresh prepared samples were well sonicated to 
break down possible aggregates. 10 µL of the suspended nanoparticles were dropped 
onto a TEM grid and dried at ambient conditions. All samples were stored in vacuum 
oven one day before imaging (room temperature).   
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4.3.2.3  Paclitaxel release from bare and LbL assembled nanoparticles 
Figure 19 shows the release profile of paclitaxel from bare nanoparticles and 
biomacromolecule LbL assembly. The accumulative release of paclitaxel from bare 
nanoparticles was used as a control in this experiment. Its release rate was the 
dissolution rate of the nanoparticles in PBS 7.4 at 37 ºC. It was observed that within 8 h, 
86 % of PAX NPs were dissolved, and free drug paclitaxel was released in the buffer 
solution. A fast burst release of paclitaxel from the bare nanoparticles was observed as 
20% of the drug was detected during the first hour. The kinetics of paclitaxel release 
from its bare nanoparticles may be influenced by its solubility, the polymorphic form, 
crystallinity, particles size and size distribution, the use of surfactant in the organic phase 
or not, and the drug encapsulation efficiency, etc.
60, 78
  
Instability and disassembly of the layers were the main causes of paclitaxel’s 
release from the self-assembly, which were induced by the environmental pH and ionic 
strength (salt concentration) changes.
79
 It was found that high salt concentration 
weakened electrostatic interactions between adjacent layers of PEs and caused the 
destruction of PE multilayer nanofilms.
54
 From Figure 18, after encapsulating these PAX 
particles with one bilayer of PEs CS/DEX, around 48.6 % of the self-assembled 
nanoparticles was released, and 32 % of four bilayers assembled nanoparticles was 
released during 8 h. (Both LbL assembled nanoparticles were conjugated with PEG.) 
80
  
A possible explanation for the release of free drug from the LbL assembly in this 
experiment could be: as the PBS buffer permeated through the polyelectrolyte layers, the 
nanoshell became unstable due to the presence of a less charged state of chitosan (in our 
case), which was caused by pH changes, resulting in the disassembly of PE layers. The 
DMSO (10% v/v) added into the aqueous phase may facilitate the dissolution of PAX 
NPs. The fewer the PE layers were, the easier the assembled structure would be 
destabilized. As the buffer went into the core, the process became the release and 
dissolution of the PAX NPs, and the drug molecules then diffused out of the 
disassembled PE layers. 
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Figure 19. Accumulative release of paclitaxel from LbL assembled nanoparticles and 
bare PAX NPs (different layer number indicated in the graph). 
 
4.3.2.4 Model fitting  
Exponential approximation model was applied to the obtained experimental data. 
(Figure 18) This simple exponential relation 
  
  
     , could be used to describe the 
general solute release behavior from different polymeric devices.
50
  
  
  
 is the fractional 
solute release, t is the release time, k is a constant, and n is the diffusion exponent, 
indicating the release mechanism. This equation can not only be used to describe the 
release of drug from slabs and cylinders, but also spherical particles. Different values of 
n can be obtained according to the geometry of the systems, suggesting different release 
behaviors of the drug from corresponding controlled release systems. Influence of device 
geometry on the release mechanism, showing that for pure Fickian release, the exponent 
n has a limiting value of 0.43 for spheres.
51 
A value of n in the range from 0.43 to 1.00 
indicated non-Fickian transport. In this release study, experimental data was fitted in the 
exponential model, and the diffusion exponent n and mechanism of the controlled 
release systems were analyzed as summed up in Table 6. The best fit curve is from the 
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experiment: the accumulative release of paclitaxel from 4 bilayer assembled 
nanoparticles. 
 
Table 7. Diffusion exponent and possible mechanism of paclitaxel release from the 
controlled release systems  
Sample ID Diffusion 
exponent n 
Constant k Possible drug  
release mechanism 
Spherical sample 
51
 0.43 _____ Fickian diffusion 
 
0.43<n<0.85 _____ Anomalous (non-Fickian) 
transport 
Bare PAX NPs 
 
0.57 0.030 Non-Fickian transport 
1 bilayer CS/DEX LbL 
assembled PAX NPs 
0.50 0.031 Non-Fickian transport 
4 bilayers CS/DEX LbL 
assembled PAX NPs 
0.55 0.013 Non-Fickian transport 
 
4.4 Conclusion 
In recent research, polyelectrolyte capsules have been widely introduced as new 
vehicles which may release therapeutic reactive due to their permeability changes in 
response to environmental stimuli.
81
 However, for further in vivo drug delivery, its 
application is limited by the requirement of extreme stimuli release mechanisms, which 
do not occur or are not applied in vivo.
79
  Naturally PE shells would only be permeable 
to molecules with MW under 5 kDa.
82
  While, in this study, PAX NPs with size under 
200 nm might be passively accumulated to pathological areas.
52
 In combination with the 
active targeting moiety, a more effective system may be formed. Stability of this 
nanoparticle based, LbL assembled drug delivery system was also expected to be better 
than that of capsules, which may be very sensitive to environmental pressure, leading to 
unexpected leakage or breakage. In all, this PAX NP based, bio-polyelectrolyte LbL 
assembled system might be a promising vehicle to deliver hydrophobic drugs or other 
macromolecules. 
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5. IN VITRO STUDY OF NANOPARTICLE RELEASES FROM PH SENSITIVE 
POLYSACCHARIDE BASED HYDROGELS* 
 
Two different kinds of dextran based pH sensitive and enzyme degradable 
hydrogels: dextran maleic acid (Dex-MA), and glycidyl methacrylated dextran (Dex-
GMA) were synthesized for oral delivery of nanoparticles. Hydrogels of both kinds were 
stable in simulated gastric fluid, but prone to swelling and degradation in the presence or 
absence of enzyme dextranase in simulated intestinal fluid. The release profiles of 
nanoparticles could be tuned under simulated human GI conditions. These two 
biodegradable hydrogels, which can release nanoparticles depending on pH changes, 
may be suitable as potential colon targeting vehicles for oral delivery of drug 
nanoparticles.
83
  
 
5.1 Introduction  
It is reported that 40 % or more of active substances are identified as poorly 
soluble in water, which has become an industry wide issue in drug discovery.
84
  The 
limitation of this kind of drug relies on its inadequate ability to be wetted and dissolved 
into the fluid in the gastrointestinal (GI) tract; therefore they exhibit low bioavailability 
in vivo.
85
  
Paclitaxel (PAX) is one of the best antineoplastic drugs found from nature in the 
past decades, and it is water insoluble. PAX NPs (PAX NPs) can be prepared by a 
solvent emulsification and evaporation method with controllable size and surface 
charges.
57
 Surface coatings and modifications can then be performed onto particle 
 
____________ 
*Parts of this section are reproduced with the permission of the Royal Society of 
Chemistry, original link: 
http://pubs.rsc.org/en/content/articlelanding/2011/sm/c1sm05729d.  
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surfaces towards specific functions, such as material biocompatibility and cell 
targeting.
18
 
Oral delivery of anticancer drugs has the advantages over current cancer 
chemotherapy, e.g. injection or infusion. Several advanced drug delivery systems have 
recently been developed for oral delivery of paclitaxel.
10-14
 One promising way is to use 
hydrotropic polymers and their micelles as vehicles and copolymerize them with acrylic 
acid. The release of paclitaxel from these vehicles can be completed within 12 hr in 
simulated intestinal fluid.
86
 Another way is to fabricate pH modulated polymeric 
microspheres containing ethyl cellulose and Eudragit
®
 to deliver small actives by an oral 
route.
87
 Biodegradable PLGA thin films were also synthesized, and the controlled 
release of paclitaxel from these films could be realized by adjusting its degradation 
rates.
77
  
Due to the physiological characteristic, a controlled drug delivery system could 
be designed to potentially regulate the drug release through external physiological pH 
changes. Moreover, the intestinal micro flora are characterized by a complex and 
relatively stable community of microorganisms, some of which are responsible for a 
wide variety of metabolic processes.
38
 Dextranases (systematic name: 1,6-α-D-glucan-6-
glucanohydrolases (EC 3.2.1.11)), which were mainly produced by the bacteria in the 
human colon, can hydrolyze the 1,6-α-D-glucosidic linkages of dextrans.88 The bacteria 
are gram negative intestinal bacteria, genus Bacteroides, which are the numerically 
predominant anaerobes in the colonic region of humans.
89
 Dextran has been found to be 
degraded in human feces due to bacterial action.
90
  Dextran pro-drugs were also shown 
to release the drug specifically in the colonic region of pigs.
91
  
Therefore, the mechanism of successfully providing colonic drug release was 
proposed to be a result of the complete stability of the hydrogel matrix in the stomach 
and small intestine followed by its disintegration, in the colonic region with a subsequent 
release of the drug.
88
 
In this study, controlled releases of the anticancer drug paclitaxel were realized 
by combining smart materials, i.e. pH sensitive polysaccharide based hydrogels, with 
45 
 
drug nanoparticles for oral administration. Dextran based pH sensitive hydrogels were 
chemically synthesized and used as the delivery vehicles to target specifically to the 
human colon (Figure 20).
41,44, 92
 PAX NPs were prepared by an optimized method named 
solvent emulsification and evaporation.
57
 
 
                   
Figure 20. Chemical structures of dextran-maleic acid and methacrylated dextran.
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5.2 Materials and methods 
Dextran from Leuconostoc mesenteroides (Mw 64,000-76,000), maleic 
anhydride, dimethyl formamide (DMF), triethylamine (TEA), lithium chloride (LiCl), 
isopropyl alcohol, glycidyl methacrylate, dimethylamino pyridine (DMAP), dimethyl 
sulfoxide (DMSO), 2,2-dimethoxy-2-phenyl-acetophenone (DMPA), N-Methyl-2-
pyrrolidone (NMP), poly (ethylene glycol) diacrylate (PEG-DA 575), acrylic acid (AA), 
Sigmacote
®
, dextranase from Penicillium sp. (25.3 units/mg solid) were purchased from 
Sigma-Aldrich Co. (St. Louis, MO, USA). Semisynthetic paclitaxel (from Taxus sp., ≥ 
97%), was also purchased from Sigma. FluoSpheres
®
 amine-modified microspheres (F-
NPs, 0.2 µm) were purchased from Invitrogen (Oregon, USA). All reagents were of 
analytical grade, and used as received. Double deionized water used for all experiments 
was obtained from a Millipore system with a specific resistance 18 MΩ/cm. 
Synthesis of Dex-MA and Dex-GMA precursors. Dextran maleic acid 
precursor (Dex-MA, degree of substitution (DS = 0.99)) was prepared by the reaction of 
dextran with maleic anhydride in the presence of the catalyst triethylamine. Briefly, 
dextran was dissolved in LiCl/DMF (10 wt %) solvent at 90 ºC under nitrogen. Then the 
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temperature was cooled to 60 ºC, and triethylamine was then added and stirred for 15 
min. The proper amount of maleic anhydride was injected to obtain the dextran 
derivative and reacted for 20 hr.
44
 The final product was precipitated, washed by 
isopropyl alcohol, and dried at room temperature in a vacuum oven. The purified product 
was stored at -20 ºC for further use. Proton nuclear magnetic resonance (
1
H-NMR) 
spectrum was recorded to calculate DS of Dex-MA.  
Methacrylated dextran (Dex-GMA) precursor was synthesized by a well 
established method.
43
 In short, dextran was dissolved in DMSO at 60 ºC under nitrogen 
for 2 hr. After dissolving 1 g of the catalyst DMAP and stirring for 20 min at room 
temperature, a proper amount of glycidyl methacrylate was added and reacted for 48 hr. 
The reaction was stopped by injecting the equimolar amount of concentrated HCl to 
neutralize DMAP. The reaction mixture was then transferred to a dialysis membrane 
(MWCO=14,000) and dialyzed for 2 weeks against deionized water at 4 ºC.
43
 Dex-GMA 
was then lyophilized, and white fluffy powder was obtained and stored at -20 ºC for 
further use. The DS of the synthesized dextran derivative was confirmed by 
1
H-NMR to 
be 6.2.  
Preparation of pH sensitive hydrogels by photocrosslinking. All hydrogels 
were formed by UV irradiation using a long wave UV lamp (UVP
®
, Upland, CA, 
U.S.A.). Different UV irradiation times were studied for the F-NPs’ release experiments 
and set to 20 min for further PAX NPs’ release experiments. Figure 18 showed the 
chemical structures of both dextran derivatives Dex-MA and Dex-GMA. PEG-DA and 
AA were added to the precursor solution and copolymerized with the dextran derivative 
Dex-MA and Dex-GMA respectively. All hydrogels were prepared in a Ø50×35 mm 
glass dish (coated with Sigmacote
®
) with a height of 1.5 mm and cut into small disks at a 
dimension of Ø8×1.5 mm.  
Loading F-NPs and PAX NPs in hydrogels. PAX NPs and F-NPs were well 
dispersed by sonication to remove any possible aggregates before they were added to the 
Dex-MA or Dex-GMA precursor solution. The sample was well mixed with 20 µL/mL 
of the photoinitiator DMPA, before being placed under the UV lamp. After a certain 
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time, semi-transparent hydrogels were formed with nanoparticles loaded within the 
networks. UV irradiation time was extended to consume all C=C bonds: 20 min or more 
for Dex-MA. The gelation time of Dex-GMA-co-AA depended on its composition. 
Double deionized water was used to wash the hydrogels three times.  
Swelling Ratio (SR). Swelling ratio of dextran based hydrogel was calculated 
based on the equation (2) in the presence and absence of enzyme dextranase. Wt 
represents the weight of the hydrogel disk at time t; Wi represents the initial weight of 
the hydrogel disk. 
SR
Wi
Wt

       (2) 
pH sensitive swelling. Hydrogel disks were placed in the buffers at different pH 
values or with pH gradient changes (from SGF 1.2 to 4.5 to SIF 6.8) to study the pH 
sensitive swelling behavior. Two buffers used were simulated gastric fluid (SGF, 
pH=1.2) and simulated intestinal fluid (SIF, pH=6.8). SGF was prepared without pepsin 
and consisted of 0.2 % (w/v) sodium chloride in 0.7 % (v/v) hydrochloric acid, the pH of 
which was adjusted to 1.2. SIF was prepared according to the USP, including 0.896 g of 
NaOH, 6.805 g of KH2PO4 in 1 L deionized water, with the pH adjusted to 6.8.  
Swelling behavior of the copolymer Dex-GMA-co-AA in the presence and 
absence of the enzyme dextranase (1.0-2.5 units/mL) was studied with buffer pH 
changed from SGF (1.2) to SIF (6.8).
92,93
  
In vitro release studies of nanoparticles from dextran based hydrogels. The 
in vitro release of F-NPs was first studied in SGF and SIF separately and then with pH 
gradient changes from 1.2 to 6.8. For the first 0-2 hr, the hydrogel disk loaded with F-
NPs was incubated in SGF; at 2 hr, NaOH and KH2PO4 were added to adjust the pH to 
4.5; after 4 hr, the buffer changed to SIF with the enzyme dextranase added (final 
enzyme concentration at 1.0-2.5 units/mL). The PAX NPs’ release experiments were 
conducted with pH gradient changes from SGF to SIF (0-2 hr, SGF; 2 hr- total release, 
enzyme concentration at 1.0-2.5 units/mL added after 15 min incubation in SIF).  
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For the F-NPs’ release experiments, one hydrogel disk (Ø8×1.5 mm) was placed 
in a 10/15 mL one-neck flask and incubated in a shaking water bath (50 rpm, 37 ºC). 50 
µL of the samples were withdrawn at a predetermined time without disturbing the disk, 
and fresh SGF/SIF was added to maintain a constant volume. For the PAX NPs’ release 
experiments, 5 disks were placed in a 10/15 mL flask and incubated in the water bath 
under the same condition. The entire 5 mL of SGF/SIF solution was withdrawn at a 
predetermined time without disturbing the disks, and the PAX NPs released were 
centrifuged down at a speed of 8500 rpm/15 min. The supernatant was restored to the 
flask and a proper amount of SGF/SIF buffer was added to maintain a constant volume. 
The particles centrifuged down were dissolved in acetonitrile/water (70/30, v/v) with 
sonication under low heat and filtered through a 0.22 µm membrane for HPLC analysis.    
Measurement of fluorescent nanoparticles’ concentration. Fluorescence 
intensity of nanoparticles was measured by a PTI QuantaMaster series 
spectrofluorometer. A calibration curve was acquired by measuring the fluorescence 
intensity of nanoparticles at different concentrations. The linear correlation parameter 
was 0.9903 with concentration ranging from 0.1 to 25 µg/mL. 
Measurement of paclitaxel concentration by HPLC. The paclitaxel 
concentration was analyzed using Waters Breeze HPLC System with a refractive index 
detector. All samples withdrawn were dissolved in the mobile phase of acetonitrile: 
water (70:30, v/v), filtered and analyzed by HPLC at a flow rate of 1 mL/min, injection 
volume of 20 µL using a reverse phase column C 18 (Nest Group. Inc., 250×4.6 mm, 
particle size 5 µm). The column temperature was set to 30 ºC, and the detector 
temperature was maintained at 35 ºC. All HPLC measurements were duplicated or 
triplicated with three parallel samples each time. A calibration curve was obtained by 
preparing standard paclitaxel (≥ 97%) and PAX NP solutions at different concentrations. 
The calibration concentration of paclitaxel in the mobile phase ranges from 5 µg/mL to 
100 µg/mL with a linear correlation parameter at 0.9984. The volume of PAX NP 
suspension dissolved ranges from 5 µL to 100 µL with a linear correlation at 0.9986. 
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SEM observation of dextran based hydrogels in different pH medium. The 
samples of dextran based hydrogels for SEM were prepared by a method named 
cryofixation.
94
 Briefly, Dex-GMA-co-AA hydrogels were incubated in PBS (pH 1.4 vs. 
7.4) for 72 hr until they reached swelling equilibrium and quickly frozen below their 
freezing points using liquid nitrogen. Both samples were then transferred to a freeze-
dryer until all water sublimed, and light-weight dry gels were obtained. Dry gels were 
stored in a vacuum oven at room temperature before SEM imaging.
94
 Samples were 
fractured during the freeze-drying process so that the surface and interior structures of 
the gel could be studied. Samples were mounted onto a stud, fixed with double-sided 
carbon tape and sputter-coated with platinum for 240 s. The surface and interior 
morphology of the hydrogels were recorded by a field emission scanning electron 
microscope JEOL JSM-7500F.  
 
5.3 Results 
One of the main obstacles present in oral delivery is the harsh environment in the 
stomach. To overcome this difficulty, pH sensitive hydrogels were developed as drug 
delivery vehicles, which could protect the nanoparticles before they reach the targeted 
location. The enzyme dextranase produced by micro flora in the human colon can 
degrade the hydrogels through an endo-hydrolysis process, and then release the 
nanospheres.
41
  
 
5.3.1 Swelling properties of dextran based pH sensitive hydrogels 
The dextran derivative, Dex-MA (DS = 0.99) may be sensitive to oxygen after 
precipitation from isopropanol. So it was suggested to dry the precipitates under inert 
gas before they were transferred to the vacuum oven. Dex-GMA was obtained as white 
fluffy powder after the lyophilization. Both dextran derivatives were stored at -20 ºC for 
further use. The synthesized dextran derivatives were characterized by 
1
H-NMR with a 
factor determined to be 0.99 for Dex-MA, 6.2 for Dex-GMA. (Figure 21) 
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1
H-NMR spectra for precursor dextran-maleic acid  
 
 
1
H-NMR spectra for precursor methacrylated dextran 
Figure 21. 
1
H-NMR spectra of dextran based precursors for synthesis of pH sensitive 
hydrogels.  
  
The Dex-MA based hydrogel was transparent with yellow color when newly 
formed by UV irradiation. The gelation time took 4 min under a long wave UV lamp, 
which was much faster than what was reported (40 min).
44
 Prolonged UV irradiation of 
51 
 
the hydrogel was preferred to be at least 20 min. Further washing by deionized water 
was performed three times to clean the gel and removed any unreacted chemicals. The 
Dex-MA disk, cut at a dimension of Ø8×1.5 mm, shrunk immediately when being 
placed in SGF, while gradually swelled until equilibrium within 5-6 hr in SIF (Figure 
22). Swelling ratio (SR) was calculated based on the initial weight of the disk. Hydrogels 
were also dried at ambient conditions until no weight changes were observed and then 
re-swelled till they reached equilibrium in SGF/SIF with the SR at 4.8 in SGF and 29.2 
in SIF (based on dry-weight). The swelling ratio depended upon medium pH, degree of 
substitution and the crosslinking density of the Dex-MA hydrogel. 
 
 
Figure 22. pH sensitive Swelling of Dex-MA hydrogel in SGF vs. SIF. (hydrogels were 
loaded with 300 µL of 1.6 mg/mL F-NPs; polymerization time 30 min; data obtained 
from triplicate of three independent experiments). 
 
White fluffy powder of Dex-GMA was obtained by lyophilization, and the final 
product was stored at -20 ºC. With acrylic acid (AA) used as a modulator and 
copolymerized within the hydrogel, pH sensitive property was obtained. Different 
compositions between Dex-GMA and AA were tested to acquire hydrogels with 
desirable swelling and mechanical property. (The AA composition was varied from 28 
% to 90 % in mass percentage, Table 8)  
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Table 8. Different compositions of Dex-GMA based copolymers 
 Dextran-GMA (mg) 
(characterization factor=6.2) 
Acrylic 
acid (µl) 
UV time 
(min) 
1 10 20 30 
2 10 30 30 
3 10 50 25 
4 10 60 15 
5 10 70 10 
6 10 87 60 
7 30 25 20 
8 30 50 20 
9 40 25 20 
10 40 50 20 
11 50 25 20 
12 50 50 20 
13 80 30 20 
 
It is known that copolymerization of acrylic acid within the hydrogel was to 
promote its pH sensitivity for resisting the gastric fluid. However, too much of this small 
monomer may jeopardize the gel’s mechanical property. With more acrylic acid 
copolymerized within the hydrogel network, it became highly water absorbent (SR could 
reach as high as 12.24, Figure 23), and ended in a fluid-like form, which may not be 
considered as a good delivery candidate. With more dextran derivative present in the 
hydrogel, the rigidness of the hydrogel increased, and the degradation behavior became 
more sensitive to the presence of enzyme dextranase. The final optimized composition of 
the Dex-GMA-co-AA hydrogel in the PAX NPs’ release experiment was 40 mg/mL of 
Dex-GMA and 52.5 mg/mL of AA. 
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Figure 23. pH sensitive swelling of Dex-GMA-co-AA hydrogel in SGF vs. SIF. 
(Composition of Dex-GMA-co-AA hydrogel: Dex-GMA 10 mg/mL, AA 87 µL/mL, UV 
irradiation time 1 hr; 300 µL of 1.6 mg/mL F-NPs loaded within the hydrogels; data 
obtained from triplicate of three independent experiments). 
 
To better simulate in vivo conditions, the swelling behavior of the hydrogels with 
pH gradient change from SGF (pH 1.2) to SIF (pH 6.8) was studied (Figure 24). At 0-2 
hr in SGF, the Dex-MA gel shrank, became compact and resisted to acidic fluid due to 
the formation of hydrogen bonds. Water trapped within the network was expelled, so the 
SR decreased. At 2 hr, as the medium switched to SIF, both kinds of hydrogels started 
swelling and reached equilibrium until 5 hr. Dex-GMA-co-AA with the enzyme added in 
the medium showed obviously extended swelling equilibrium time till 10 hr and higher 
SRs. The explanation could be: enzyme dextranase needs time to diffuse in and degrade 
the hydrogel, so the time required to reach swelling equilibrium was prolonged; after the 
component Dex-GMA in the hydrogel Dex-GMA-co-AA was degraded, a relatively 
loose network was left, leading to absorption of more water and thus a higher SR. UV 
polymerization time did not affect SR much. The Dex-MA copolymerized with PEG 
also showed similar swelling behaviors to Dex-MA hydrogel.  
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Figure 24. pH sensitive swelling of dextran based hydrogels with pH gradient change. 
(500 µL of 1 mg/mL well sonicated PAX NPs were loaded within the hydrogel 
networks; UV irradiation time was 20 min; Dex-GMA-co-AA composition at 40 mg/mL 
of Dex-GMA and 50 µL/mL of AA. Data was obtained from at least duplicate of two 
independent experiments). 
 
5.3.2 In vitro release studies of fluorescent nanoparticles (F-NPs) from dextran 
based hydrogels 
 
5.3.2.1 Release studies of F-NPs from dextran based hydrogels in simulated gastric fluid 
vs. simulated intestinal fluid (SGF vs. SIF) 
The release studies of F-NPs from different hydrogels were performed in 
SGF/SIF in the presence and absence of dextranase (1.0-2.5 units/mL) in a shaking water 
bath (50 rpm, 37 ºC).  The release profiles were obtained by measuring the mass 
percentage of released F-NPs (i.e. Mt/M∞) at specific times.  
From Figure 25, it is suggested that both dextran based hydrogels were stable in 
SGF with less than 10 % of F-NPs released within the first 24 hr; while, in SIF, both 
hydrogels were degraded totally within 8-10 hr and released all the fluorescent 
nanoparticles loaded.  
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Figure 25. Different release profiles of F-NPs from dextran based hydrogels in SGF vs. 
SIF. (Dex-MA: 30 min UV irradiation, Dex-GMA-co-AA 1 hr UV; all hydrogels were 
loaded with well-sonicated 300 µL of 1.6 mg/mL F-NPs; data obtained from the 
triplicate of three independent experiments). 
 
For the hydrophobic drugs’ release from thin polymer films, a three – stage 
release model was proposed to describe the underlying release mechanisms and kinetics: 
burst release, relaxation induced release and diffusion release.
77
 This model may also 
apply in our case with some modifications. In the beginning, the burst release of 
nanoparticles occurred with less than 15 % observed in SIF, probably caused by the F-
NPs loosely staying on the hydrogel surfaces. As the SIF solution (with dextranase at 
1.0-2.5 units/mL) diffused in the hydrogel, polymer chains were hydrated and the 
network expanded. This took about 2-3 hr; during this time, nanoparticles were still 
trapped. With sufficient swelling and enzyme induced degradation, the hydrogels broke 
down with nanoparticles leaking out of the gel, or the hydrogel pores reached a certain 
size at which the nanoparticles (size of the F-NPs: 200 nm or less) could diffuse out 
freely, and thus the release started. Due to the circuitous internal structure of the gels, 
nanoparticles diffused through paths of different hindrance. This would take as long as 
10 hr for both kinds of dextran based pH sensitive hydrogels to totally release all the F-
NPs. The final release reached over 80% of the initial amount of nanoparticles; the rest 
may have been lost during centrifugation or deviation when taking the sample. The 
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significant difference between nanoparticles’ release profiles in different pH medium, 
i.e. SGF/SIF, suggested that these dextran based hydrogels could be regarded as 
promising vehicles for colon targeting delivery of nanoparticles through the oral route. 
 
5.3.2.2 Release study of F-NPs in SIF in the absence of enzyme dextranase 
 
The Dex-MA hydrogel was also used to study the release of F-NPs in the 
absence of the enzyme. (Figure 26) As a result, this dextran based hydrogel could be 
degraded through the polymer chain hydration, but it is suggested to be a very slow 
process as compared with enzyme induced degradation. In the first 6 days, only less than 
10 % of F-NPs were released, possibly due to the burst effect. More F-NPs were 
gradually released from day 7 till day 12 with the gel totally broken and dissolved, and 
then all the particles were released after 12 days. Since the retention time for oral drug 
formulation in the gastrointestinal (GI) tract is known to be 14-16 hr, and it is desirable 
for the delivery vehicle to release all the PAX NPs within 20 hr.
87
 The enzyme 
dextranase was added in the following release experiments.  
 
 
 
Figure 26. Release of F-NPs from Dex-MA hydrogel in SIF without dextranase. 
(Sodium azide added at a concentration of 0.025 % w/v, and results were based on 2 
independent experimental data with three parallel samples in each experiment.)  
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5.3.2.3 Tunable release profiles of F-NPs from different dextran based hydrogels  
To better simulate in vivo situation, the pH of the medium used to study the F-
NPs’ release from the hydrogels was changed gradually from SGF (pH 1.2), SGF/SIF 
(pH 4.5), to SIF (pH 6.8). Four different dextran based hydrogels were prepared under 
different UV irradiation times and varied compositions. 
 
 
Figure 27. Tunable release profiles of F-NPs from dextran based hydrogels under 
different conditions. (Results were triplicated with three parallel samples each time; 
0.025 % w/v of sodium azide was added in the solution when necessary). 
 
Gelation time for the Dex-MA hydrogel was 4-5 min, which was shorter than 
that reported.
44, 47
 The Dex-MA hydrogel prepared by 5.5 min UV irradiation was not as 
strong as gels prepared by the longer UV time, e.g. 20-30 min. After switching from 
SGF to SIF, the hydrogel edge became blurred, and an immediate release of F-NPs was 
observed with a total release at 6 hr (Figure 27). A longer UV irradiation time was 
desirable for this Dex-MA based hydrogel, because the double bonds, which participated 
in the crosslinking reaction, were present in the middle of the MA segment in Dex-MA, 
and polymerization might be hindered by the adjacent carboxylic acid and dextran 
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macromolecules.
44
 Non-uniform and less cross-linked hydrogel networks may be formed 
by insufficient UV irradiation. When the polymerization time was extended to 30 min, 
all active double bonds were expected to be consumed, and a better cross-linked 
hydrogel was obtained. A steadily increased release of nanoparticles from the Dex-MA 
hydrogel was observed from 4 hr to 11 hr (Figure 27). Tunable release profiles could be 
obtained by copolymerizing Dex-MA with enzyme non-degradable component PEG-
DA. In our case, as 5 µL/mL of PEG-DA was added in the Dex-MA precursor solution 
to form the gel, a slower release profile of F-NPs was obtained with the complete release 
extended up to 24 hr. PEG was not degraded by dextranase, so it was left as white 
precipitates in the end. Another kind of dextran based hydrogel was copolymer Dex-
GMA-co-AA. Methacrylated dextran has been widely used as a vehicle for delivering 
small drug molecules.
11, 93, 95 
For oral delivery of nanoparticles, copolymerization with 
AA could help the gel to resist gastric fluid. The AA composition was examined in a 
range from 28 % to 90 % (mass percentage), and the hydrogel Dex-GMA-co-AA formed 
with a higher amount of AA was soft, super water absorbent, and released all the F-NPs 
within 23 hr. Considering that the mechanical property may not be suitable as a delivery 
vehicle, the composition was optimized to 40 mg/mL of Dex-GMA and 50 µL/mL of 
AA for further experiments.  
 
5.3.3 Release of PAX NPs from Dextran Based Hydrogels 
PAX NPs (PAX NPs) were prepared by a modified solvent emulsification 
evaporation method with the size at 110 ± 10 nm and zeta potential at -42 ± 2.6 mV. 
PAX NPs were loaded within three different dextran based hydrogels, and the release 
behaviors of these particles were studied with the hydrogel property adjusted and the 
buffer pH changed from SGF (pH 1.2) to SIF (pH 6.8 with dextranase 1.0-2.5 units/mL).  
 
 
59 
 
 
 
 
Figure 28. Tunable release of PAX NPs from dextran based pH sensitive hydrogels with 
adjusted properties (top); first 12 hrs of PAX NPs’ release from different dextran based 
hydrogels (bottom). (Dex-GMA-co-AA composition at 40 mg/mL of Dex-GMA and 50 
µL/mL of AA) (Results were at least duplicated with three parallel samples each time, 
0.025 % w/v of sodium azide added in the solution.) 
 
Figure 28 showed the release profiles of PAX NPs from different dextran based 
hydrogels and the detailed information in the first 12 hr. For the hydrogel Dex-MA, it 
first shrank in SGF with a burst release of PAX NPs up to 30 % observed. Particles 
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loosely adhered onto the hydrogels were possibly released at this time. The releases of 
PAX NPs from the Dex-MA hydrogels took a much longer time than those of the F-NPs 
did. This may be due to the different conditions between F-NPs (300 µL of 1.6 mg/mL 
solid spheres) and PAX NPs (500 µL of 1.0 mg/mL, paclitaxel loaded in the particles 
with E.E. at (31 ± 0.08) %). The Dex-MA hydrogel could be totally hydrolyzed by the 
enzyme dextranase with no residues left in the end. For the Dex-MA-co-PEG hydrogel, 
at the same concentration of Dex-MA, PEG was copolymerized within the network, and 
a denser hydrogel was formed with a slower release profile obtained. For both Dex-MA-
co-PEG and Dex-GMA-co-AA hydrogels, only 12 % of PAX NPs was released in SGF 
during the first 2 hr, less than that from the hydrogel Dex-MA itself. In the next 8 hr, 
only 37 % of PAX NPs was released from both copolymers, as compared to over 60 % 
of PAX NPs released from the Dex-MA. Total release of PAX NPs was 72 hr from the 
hydrogel Dex-MA-co-PEG with non-degradable white precipitates observed in the end. 
For the Dex-GMA-co-AA hydrogels, sustained release profiles of PAX NPs were also 
obtained with the total release time of PAX NPs extended over 100 hr. The composition 
between Dex-GMA and AA could be adjusted to achieve desired release profiles of PAX 
NPs.  
The release of nanoparticles from the Dex-MA based hydrogels was proposed as 
a degradation-controlled process. The release mechanism of PAX NPs could be 
described: in SGF, the gel could trap most drug nanoparticles within the first two hours. 
As the medium switched to SIF (pH 6.8), carboxylic acid group in the MA section was 
ionized and the hydrogel started swelling and degrading, resulted in gradual breakdown 
of the networks and PAX NPs’ release. While, for the Dex-GMA-co-AA based 
copolymer, in the presence of enzyme dextranase in SIF, a higher SR was observed and 
the diffusion-controlled drug release would be dominant. Since only the dextran based 
component could be degraded, a soft and loosely cross-linked hydrogel was formed after 
3-4 hr incubation in SIF. This degradation induced higher swelling created pores large 
enough for drug particles to diffuse out. A higher AA composition was used for the F-
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NPs’ release experiment, and no gel was left after the dextran degradation since the AA 
based hydrogel was totally dissolved.  
 
5.3.4 SEM images of dextran based hydrogels 
 
 
 
Figure 29. SEM images of cryo-fixed hydrogels Dex-GMA-co-AA (10 mg/mL of Dex-
GMA and 85 µL of AA) in PBS 1.4 (left) vs. PBS 7.4 (right). Top images showed 
characteristic internal pore structures; bottom images showed surface structures of the 
gels. Samples were prepared by swelling the gel until equilibrium and quickly 
transferred into a chamber filled with liquid nitrogen; a three-day freeze-drying process 
was followed, and then stored in a vacuum oven at room temperature before SEM 
imaging. 
 
Figure 29 showed the SEM observation of internal and surface morphology of 
the dextran based hydrogels after they reached swelling equilibrium in PBS at different 
pH values (7.4 vs. 1.4). This could be considered as a reference to understand the 
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particles’ diffusion-controlled release from the Dex-GMA-co-AA hydrogel. Highly 
swollen hydrogels in PBS pH 7.4 exhibited pores large enough for particles to diffuse, 
while the hydrogels in pH 1.4 shrunk with a tightly packed network and more tortuous 
interior structures formed, trapping the nanoparticles within the hydrogels. 
 
5.4 Conclusions  
Two polysaccharide dextran based pH sensitive hydrogels Dex-MA and Dex-
GMA-co-AA have been produced by the photocrosslinking reaction with both 
fluorescent NPs (F-NPs) and hydrophobic drug PAX NPs loaded within the networks. 
Adjustable release profiles of both F-NPs and PAX NPs were obtained by 
copolymerizing with PEG-DA (575) or optimizing the composition ratio between Dex-
GMA and AA. The resulted two hydrogels showed good pH responsive swelling 
property. A higher SR was observed for Dex-GMA-co-AA hydrogel at a composition of 
40 mg/mL of Dex-GMA and 50 µL/mL of AA in the presence of the enzyme dextranase. 
A fragile Dex-MA hydrogel was synthesized with a faster release of the F-NPs observed 
under a shorter UV photocrosslinking time. The sustained release profiles of F-NPs were 
obtained for both Dex-MA-co-PEG and Dex-GMA-co-AA hydrogels. Two release 
mechanisms were proposed: degradation controlled and diffusion controlled. 
Considering the more complicated environment in vivo, stronger hydrogels with 
extended release profiles would be desirable. The two Dex-MA-co-PEG and Dex-GMA-
co-AA hydrogels developed here, could release PAX NPs up to 5 days with 40 % of the 
PAX NPs released during the first 12 hr. Based on these results, it is suggested that both 
the Dex-MA and Dex-GMA-co-AA hydrogels could be considered as potential colon 
targeting vehicles for delivering nanoparticles orally.  
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6. IN VITRO EVALUATION OF MODIFIED NANOPARICLES  
 
In this study, polystyrene nanoparticles were first modified by both synthetic 
polymers and biomacromolecule chitosan and dextran. The anticancer drug paclitaxel 
core was replaced temporarily so as to characterize the surface morphology 
nanoparticles encapsulated by different types of polyelectrolytes, optimize conjugation 
conditions for the surface functional groups, and evaluate in vitro material 
biocompatibility and targeting group functionality with cells. A preliminary study on the 
stability of the nanoparticles in simulated intestinal fluid (SIF) was also investigated in 
this section.  
 
6.1 Introduction  
Tumor cells are abnormal cells that grow uncontrollably, and tumor blood 
vessels possess a number of different properties from those in normal tissue.
96
 Especially 
in the rapidly growing and large solid tumors, new blood vessels are often deficient in 
interrupted or absent membranes, leading to unstable blood flow.
97
 This phenomenon 
together with a poorly developed lymphatic network results in an effect called “passive 
targeting”.98 Sufficient concentration, traversing through the tumor microcirculation, 
diffusing into the interstitium, and remaining at the site for the duration to induce a 
therapeutic effect are requirements for an antitumor drug therapy to be effective.
99
 A 
solid hydrophobic anti-cancer drug core, coated with different hydrophilic polymer thin 
films, and modified by a biocompatible group and a cell targeting group, therefore may 
offer a promising solution to meet all the requirements. Of these characteristics, the 
efficient binding and uptake capability with specific tumor cells is the key. 
Transformed or cancerous cells often express different amount of glycans 
compared with their normal counterparts. Lectin is a protein that can recognize and bind 
to sugar complexes due to its high specificity for the chemical structure of the glycans. It 
has been suggested that the lectin wheat germ agglutinin (WGA) conjugated 
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nanoparticles will allow efficiently targeting to cancer cells.
28
 Recently it has also been 
demonstrated in vitro that it may be possible to exploit the increased WGA binding 
capacity exhibited by Caco-2 cells compared to that of non-cancerous human 
colonocytes to build a more efficient tumor-specific drug delivery system for colon 
cancer chemotherapy.
29
  
For the nanoparticle based cancer chemotherapy, there are two aspects that have 
attracted our close attention: the size and the surface modification of the drug loaded 
nanoparticles. It has been found that the size of the particles plays a key role in their 
adhesion to and interaction with the biological cells.
100
 The possible mechanisms for the 
particles to pass through the gastrointestinal and other barriers could be: paracellular 
passage – particles "kneading" between intestinal epithelial cells due to their extremely 
small size (<50 nm); endocytotic uptake – particles adsorbed by intestinal enterocytes 
through endocytosis (particles size < 500 nm); lymphatic uptake – particles adsorbed by 
M cells of the Peyer’s patches (particle size < 5 microns).6 Lectin mediated cell binding 
and uptake of the nanoparticles with the size below 500 nm combines the passive 
accumulation with active targeting, which belongs to the second mechanism as described 
above.  
The monolayer of Caco-2 cells, which are derived from human colorectal 
adenocarcinoma, has been widely used as an in vitro model of the gastrointestinal 
epithelium for a number of years.
101
  It is considered as a valuable source for 
investigating the interaction between active compounds and the lining of the small 
intestine before initiating animal studies.
102
 In this research, it will be used as the tumor 
cell model to investigate the material compatibility and cell uptake efficacy of the lectin 
mediated nanoparticles. 
 
6.2 Material and Methods 
Poly (allylamine) hydrochloride (PAH, Mw~70 000 g/mol), Poly(4-
styrenesulfonic acid-co-maleic acid) sodium salt (PSSCMA, Mw~20,000 g/mol), 
chitosan (low molecular weight), carboxyl methyl dextran (average Mw > 500,000), 
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poly (vinyl alcohol) (PVA, Mw 9000-12,000 g/mol and Mw 22,000 g/mol), sodium 
alginate (from brown algae, low viscosity) were purchased from Sigma-Aldrich, USA. 
Semisynthetic paclitaxel (from Taxus sp.), ≥ 97% was purchased from Sigma.  Poly 
(ethylene glycol) (NH2-PEG-CM, Mw ~ 3400) was purchased from Laysan Bio, Inc. 
USA. FITC labeled wheat germ agglutinin (F-WGA) was purchased from Sigma, USA. 
Caco-2 cells and EMEM (Eagle’s minimum essential medium) were purchased 
American type culture collection (ATCC, USA). Fetal bovine serum (FBS) was 
purchased from Fisher scientific, USA. Live/dead® cell viability assay, Alexa Fluor
®
 
647 hydrazide, polystyrene latex (PS NPs, 0.2 µm), and FluoSpheres® sulfate-modified 
microspheres (F-NPs, 0.2 µm) were purchased from Invitrogen (Oregon, USA). 
Ultrapure water used for all experiments and cleaning steps was obtained from a 
Millipore system with a specific resistance 18 MΩ/cm. Polyelectrolyte solutions were 
prepared in 0.15 M NaCl. Phosphate-buffered saline solution (PBS, pH 7.4) consisted of 
1.1 mM potassium phosphate monobasic, 3 mM sodium phosphate dibasic heptahydrate, 
and 0.15 M NaCl. 
Preparation of PS LbL self-assembled nanoparticles. Core-shell structured 
nanoparticles were built by a well-established method named LbL self-assembly (section 
2). Polystyrene nanoparticles were used first to test the feasibility of building a core-
shell system and conjugating with functional groups PEG and F-WGA. Fluorescent 
nanoparticles were used to study the stability of LbL assembly on spheres.  
Characterization of self-assembled nanoparticles. Particles before and after 
the LbL assembly and modifications were characterized by transmission electron 
microscopy (TEM) and scanning electron microscopy (SEM).  
Caco-2 cell cultivation. Caco-2 cells were routinely cultured in EMEM, 
supplemented with 20% (v/v) of fetal bovine serum (FBS) and 1% (v/v) of streptomycin-
penicillin solution, at 37 ºC in a 5% CO2 incubator. For the F-WGA binding and uptake 
experiment, cells were trypsinized and washed by PBS before use.  
In vitro Caco-2 biocompatibility studies. Cell compatibility of CS/DEX and 
PEG encapsulated nanoparticles was evaluated in vitro using Caco-2 cells. Viability of 
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cells were studied by fluorescence microscopy using a standard protocol of live/dead® 
cell viability assay. Percentage ratio between viable cells and total cell number was 
calculated using a cell counter for all parallel samples (n = 4).  
Confocal laser scanning microscopy. This microscope utilizes an inverted DMI 
6000 microscope which is equipped with three excitation laser lines 488, 543 and 633 
nm and 10x, 40x, 63x objectives. The particles prepared by the self-assembly method at 
different F-WGA concentrations interacted with Caco-2 cells for 20 h at 4 ºC and 
suspended in the sterile PBS for confocal microscope imaging. Both bright field and 
fluorescent images were recorded by the 63x objective. 
Fluorescence microscopy. LIVE/DEAD
®
 viability/cytotoxicity assay kit is a 
two-color fluorescence cell viability assay that can determine live and dead cells by 
recognizing the intracellular esterase activity and plasma membrane integrity. 
Concentrations of the two dyes were optimized first to reduce the interference. 
Fluorescence microscopy with green and red excitation laser lines was used to study the 
live/dead states of cells. Polystyrene nanoparticles (PS NPs) were used as the blank 
control, and self-assembled PS NPs (3 bilayers of CS/DEX, CS/DEX: 1 bilayer of 
particles’ encapsulation with chitosan and carboxyl methyl dextran/dextran-sulfate) with 
and without PEG modification were tested.  
Fluorescence activated cell sorting (FACS). A number of fluorescent labeled 
cells was analyzed by FACS. Caco-2 cells were cultivated at a density of 4 ×10
5 
cells/mL. Three different kinds of particles (fluorescent nanoparticles, fluorescent 
particles encapsulated with CS/DEX-PEG, particles encapsulated with CS/DEX-PEG in 
conjugation with F-WGA) were prepared and then contacted directly with suspended 
cells for 20 h at 4 ºC. A low temperature was used to facilitate surface binding of 
nanoparticles and the analysis by FACS. Caco-2 cells were used as the reference before 
analyzing all samples. 20,000 – 40,000 cells were counted for each sample (n = 3) and 
the experiments were triplicated. 
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6.3 Results  
6.3.1 TEM and SEM images of chitosan/dextran encapsulated PS NPs 
 
Figure 30. Zeta potential of chitosan/dextran encapsulated PS NPs (3 bilayers). 
 
  
Figure 31. TEM images of CS/DEX LbL assembled PS NPs. (3 bilayers). From left to 
right: 1) PS NPs; 2) 5 bilayers of PAH/PSSCMA encapsulated PS NPs (each layer 2nm); 
3, 4) 3 bilayers of CS/DEX encapsulated PS NPs (each layer 5nm). Fresh prepared 
samples were well sonicated to break down possible aggregates. 10 µL of the suspended 
nanoparticles were dropped onto a TEM grid and dried at ambient conditions. All 
samples were stored in the vacuum oven one day before imaging (room temperature).   
 
Two different kinds of dextran polyelectrolytes were used in this experiment: 
dextran-sulfate and carboxymethyl dextran (Dex-CM). Dextran-sulfate is a strong anion, 
and usually easily adsorbed onto the cationic surfaces. But for further modification with 
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PEG (H2N-PEG-COOH) using the carbodiimide chemistry, a polyelectrolyte with 
carboxyl group is adsorbed onto the outermost layer of the nanoparticles. Dex-CM is a 
weak anion with a carboxyl group modified on the dextran branches. It was used here to 
replace the dextran-sulfate. For weak ions, the pH was adjusted to be 6.5 for Dex-CM 
and 4.0 for chitosan, and they were both encapsulated onto PS NPs (3 bilayers). (Figure 
30)   
TEM images showed the size and morphology of LbL assembled PS NPs (Figure 
31). 3 bilayers of biomacromolecules chitosan and dextran were encapsulated onto PS 
NPs (two images on the right), showing a rougher surface as compared with those of 
bare PS NPs (left) and PS NPs encapsulated with 5 bilayers of synthetic polymers (2
nd
 
from the left). This may be due to the glucose ring that exists in the structure of these 
polysaccharides. Smooth surfaces with fine textures were observed after adsorbing 
synthetic polyelectrolytes onto the particles. These results were consistent with the 
literature, which used biomacromolecules chitosan and heparin as the polyelectrolytes.
13
 
The pH and ionic strength/salt concentration are two factors that affect the charge state 
and conformation of the polyelectrolyte chains, which further influence the layer 
thickness of the polyelectrolyte.
13
 Chitosan layer with lower molecular weight was able 
to grow faster, and the pH of the medium affected the charge state of chitosan (pKa of 
chitosan is 6.5-7.3).
64
 Different ionic strengths of the incubating medium were used for 
synthetic and bio-polyelectrolytes, and the obtained nanofilms were different in 
thickness. Biomacromolecules chitosan and hyaluronan were observed to form a uniform 
film after only a few depositions at a high salt concentration (e.g. 0.15 M), while it is 
very difficult to buildup the film at a low salt concentration, e.g. 10
-4
 M NaCl.
64
 The 
thickness of one polyelectrolyte layer was around 5 nm for each bio-macromolecule 
CS/DEX layer, and 2 nm for the synthetic polymer PAH/PSSCMA layer under the 
experimental ionic strength and the pH of the buffers. (i.e. concentration: 20 mg/mL for 
PAH/PSSCMA in 30 mM KCl; 2 mg/mL for CS/DEX in 0.15 M NaCl; Data were 
obtained from analysis of the SEM/TEM images.) 
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Figure 32. SEM images of PS NPs (left), CS/DEX layer-by-layer assembled PS NPs 
(middle image, 3 bilayers) and self-assembled PS NPs conjugated with PEG and F-
WGA (right image, 3 bilayers of CS/DEX). Fresh prepared samples were well sonicated 
to break down possible aggregates. 10 µL of the suspended nanoparticles were dropped 
onto a TEM grid and dried at ambient conditions. All samples were stored in vacuum 
oven one day before imaging (room temperature).   
 
SEM images may provide more information about the surface morphology of the 
nanoparticles.  Figure 32 showed the images of PS NPs, CS/DEX self-assembled 
nanoparticles and their further modification with PEG and WGA. The original PS NPs 
were white spheres, and after being coated with CS/DEX layers, the color turned darker, 
possibly due to the presence of high atomic number element S in the DEX layer. Surface 
scanning of the particles with CS/DEX layers (middle image) showed sticky surfaces as 
compared with the original polystyrene particles (left image). Further covalently binding 
with PEG (NH2-PEG-CM, Mw~ 3400), particles tended to stabilize themselves in 
suspension and could be easily re-dispersed, possibly under the repulsion effect among 
the flexible PEG chains (carboxymethyl group present in the PEG). The particles were 
further conjugated with F-WGA; it was shown that they became agglomerated and 
sonication could help to reduce the particles’ aggregation at this time.  
 
6.3.2 Stability of LbL assembled nanoparticles 
Methods to study the stability of polyelectrolyte assembled nanospheres were 
still under development, and it is difficult to find a proper way to quantify the disruption 
of layered structure and disassembly of the shell. However, measurements of the 
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particles’ zeta potential could provide one possible way for studying the stability of 
particles in suspension.  
In this section, chitosan/dextran polyelectrolyte layer was encapsulated onto 
fluorescent nanoparticles (F-NPs). Zeta potential was monitored after incubating the LbL 
assembled nanoparticles in SIF for certain times, and fluorescence intensity before and 
after polyelectrolytes’ adsorption onto the particles was also measured.  
 
6.3.2.1 Measurement of zeta potential  
Figure 33 showed the zeta potential of different modified PS nanoparticles 
incubated in SIF. The PS nanoparticles as a control showed a zeta potential at -35 mV. 
The particles with DEX-CM as the outmost layer (1 bilayer) were not as stable as 
particles with PEG surface modification, based on the relatively smaller zeta potential 
(absolute value) of PS-1bilayer (PS-1bi) without PEG. It seemed that the 1 bilayer 
assembled particles could maintain the same surface charge within 22 h in SIF at 37 ºC.  
During the first 2 h, the particles with PEG conjugation still showed zeta potential below 
-25 mV, and the standard errors were small, suggesting they were still stable in the 
suspension. The particles encapsulated with 5 bilayers of P.E. were easily disturbed by 
the SIF, even after conjugating the surface with PEG. T test was performed to study the 
statistical significance of the above data. (Table 9, tails=2, type=2) 
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Figure 33. Zeta potential of particles with different CS/DEX layer numbers incubated in 
SIF. PS: polystyrene nanoparticles as a control; PS–1bi: particles with 1 bilayer of 
CS/DEX; PS-1bipeg: 1 bilayer of CS/DEX encapsulated particles in conjugation with 
PEG; PS-5bipeg: 5 bilayers of CS/DEX built onto particles modified with PEG. All 
measurements of zeta potential were done 3 times for each of the three parallel samples. 
Independent experiments were at least duplicated.  
 
Table 9. p values from t-test of the zeta potential data under different conditions 
 
 
6.3.2.2 Measurement of fluorescence intensity 
At time t = 0 h (Figure 34), the fluorescence intensity of particles with CS/DEX 
or CS/DEX-PEG layers were reduced to less than 40% of the original intensity of bare 
F-PS nanoparticles. The fluorescence intensity of particles with 5 bilayers of the 
polyelectrolyte layers and PEG modification was decreased to 16.6 %. This is due to the 
coverage of the polyelectrolyte layers on the particles’ surfaces that masked the 
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fluorescence. (There may also be some particles lost during the washing and 
centrifugation steps during the LbL procedure).  
 
 
Figure 34. Fluorescence intensity of particles with different polyelectrolyte layers 
incubated in SIF under different time intervals. (PS at concentration 1.6 mg/mL).  
 
After incubating the particles in SIF under different conditions for some time, the 
fluorescence intensity of particles with 1 bilayer coating and PEG surface modification 
were maintained over time; while, without the PEG conjugation, particles may have a 
disrupted structure, and fluctuated fluorescence intensity over time. Particles with higher 
polyelectrolyte layer number may be more easily interrupted on their surfaces.    
From Figure 34, 1 bilayer CS/DEX encapsulated nanoparticles conjugated with 
PEG was also observed showing similar fluorescence intensity as compared with the 
nanoparticles without PEG modification. This may be attributed to the fact that PEG 
layer was not covering onto the particles’ surfaces, but extended as flexible chains into 
the solution.(Samples were nanoparticles in suspension)  
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6.3.3  F-WGA conjugation onto nanoparticles 
WGA can selectively bind to N-acetyl glucosamine and N-acetylneuraminic acid 
residues. Nonspecific adhesion during the carbodiimide chemical reaction was studied 
first at different polyelectrolyte layer numbers and types. 
 
6.3.3.1 Nonspecific adhesion – polyelectrolyte layer number 
Nonspecific adhesion is usually caused by undesired reactions. Alexa Fluor® 
647 hydrazide was used first to test the feasibility of conjugating F-WGA onto layer-by-
layer self-assembled nanoparticles and study the effect of different assembled layer 
numbers on nonspecific adhesion. This fluorescence reagent has an active amine group, 
so it can react with the carboxylic acid group through the carbodiimide reaction. EDAC 
(1-ethyl-3-(3-(dimethylamino) propyl) carbodiimide) was used as the carbodiimide to 
promote the formation of the amide bond. S-NHS (N-hydroxysulfo succinimide) was 
added to form a more stable intermediate product. The nonspecific adhesion study of 
Alexa Fluor® 647 on the nanoparticles was performed by mixing both the dye and 
particles without adding carbodiimide and s-NHS.  
Figure 35 shows that, as the layer number increased, the fluorescence intensity of 
Alexa Fluor® 647 conjugated nanoparticles decreased. The reason might be: the higher 
coverage of particles with more polyelectrolyte layers, the less frequently nonspecific 
adhesion of Alexa Fluor® 647 occurred. 
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Figure 35. Effect of different layer number assembled PS NPs on non-specific adhesion 
of Alexa Fluor® 647 hydrazide (polyelectrolyte layer PAH/PSSCMA). 
 
6.3.3.2 Nonspecific adhesion – polyelectrolyte type 
 
Figure 36. Effect of the polyelectrolyte type (bio vs. synthetic) on nonspecific adhesion 
of F-WGA conjugated onto LbL assembled nanoparticles. Blank – layer-by-layer treated 
polystyrene nanoparticles (LbL PS NPs); Negative – nonspecific adhesion of F-WGA on 
LbL treated PS NPs; Tagged – LbL treated PS NPs reacted with F-WGA in the presence 
of EDC and s-NHS; Syn-synthetic polyelectrolytes.  
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Here fluorescence labeled WGA was used as a targeting moiety to Caco-2 cells. 
Both synthetic PAH/PSSCMA and bio-polyelectrolytes CS/DEX were encapsulated onto 
the particles with PEG modification, and WGA were then conjugated to the outmost 
layer.  
From Figure 36, the highest fluorescence intensity was observed when 
conjugating the LbL assembled particles with F-WGA in the presence of EDC/s-NHS, as 
compared with blank and negative controls. This is due to the successful formation of 
the covalent amide bonds between F-WGA and the particles’ outmost layer. Nonspecific 
adhesion of bio-polyelectrolyte CS/DEX was higher than that of synthetic 
polyelectrolyte PAH/PSSCMA. (PEG was conjugated to all the particles’ surfaces after 
LbL self-assembly) In solution, wheat germ agglutinin exists as a heterodimer with a 
molecular weight of approximately 38,000 Daltons and is normally cationic under 
physiological conditions. This may cause higher affinity of the F-WGA to 
biomacromolecule CS/DEX than that of synthetic PAH/PSSCMA.  
The wavelength corresponding to the maximum fluorescence intensity shifted 
after conjugating F-WGA onto the particles’ surfaces, 528 nm and 535 nm for 
biomacromolecules and synthetic polymers respectively. (For F-WGA itself, the 
maximum fluorescence is at 519 nm wavelength.) Conjugation efficiency was calculated 
according to the F-WGA concentration at the maximum fluorescence intensity over the 
initial amount of F-WGA added in the reaction, which was 36.7% (after 3 bilayers of 
CS/DEX encapsulated PS NPs and PEG conjugated). The average F-WGA concentration 
(at max. intensity) on particles’ surfaces was 102 µg/mL, as obtained from the standard 
curve of WGA concentration versus fluorescence intensity (n=3). 
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6.3.4 Interaction between F-WGA modified polyelectrolyte assembled 
nanoparticles and Caco-2 cells 
6.3.4.1 Effect of WGA/nanoparticle concentration on Caco-2 cell binding/uptake 
capability 
 
 
Figure 37. F-WGA conjugated, LbL assembled nanoparticles at different F-WGA 
concentrations in contact with Caco-2 cells. (20 h at 4 ºC) (Left to right, 1.5, 7.5, 15 
µg/mL of F-WGA on the nanoparticle surfaces; 3 bilayers of CS/DEX assembled) 
Images are based on the same settings of the confocal microscope at the magnification 
63×.  
Confocal microscopy was used first to study the interaction between F-WGA 
conjugated, LbL assembled nanoparticles with suspended Caco-2 cells. The 
concentration of F-WGA on LbL nanoparticles was calculated according to the 
fluorescence intensity of the particles from F-WGA after conjugation. Three 
concentrations of F-WGA on particle surfaces were used, 1.5, 7.5 and 15 µg/mL (Figure 
37). Particles contacted with cells for 20 h at 4 ºC. This temperature was set to avoid 
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energy dependent particle uptake behavior. So the particles were expected to bind only 
on the cell surfaces.  
FACS stands for fluorescence associated cell sorting, which can differentiate 
fluorescent labeled cells from non-labeled ones and separate cells with fluorescence at 
different wavelengths. Cells were washed three times with PBS after the incubation. 
Caco-2 cells were used as a blank control, and all the gating results were based on this 
sample. The concentration of WGA on particles’ surfaces ranged from 1.5 to 15 µg/mL. 
20,000 cells were counted for each sample (n = 3), and the experiments were triplicated 
(Figure 38). 
 
 
Figure 38. Effect of WGA/nanoparticle concentration on Caco-2 cell binding capability. 
 
The percentage of fluorescence associated cells was calculated from the cells 
being bound with fluorescent WGA, which was conjugated onto the LbL assembled PS 
NPs. These results indicated the capability of Caco-2 cells binding with F-WGA 
modified NPs at different concentrations. The concentration of the F-WGA on particles’ 
surfaces at 7.5 µg/mL showed more than 40% of the cells were bound with the particles. 
Further increase of the F-WGA concentration to 15µg/mL, the percentage of the labeled 
cells could reach 60%. At a higher temperature, e.g. 37 ºC, the binding and uptake of 
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nanoparticles by the cells may be more efficient than at 4 ºC, at which certain enzyme 
activity related to this process might be suppressed.  
 
6.3.4.2 Effect of F-WGA as a targeting group to Caco-2 cells 
The effectiveness of F-WGA as a targeting group to Caco-2 cells was also 
investigated by FACS (Figure 38). Three different kinds of particles (fluorescent 
nanoparticles, fluorescent particles encapsulated with CS/DEX-PEG, particles 
encapsulated with CS/DEX-PEG in conjugation with F-WGA) were prepared and then 
incubated with cells for 20 h at 4 ºC. The fluorescence of the cells counted by flow 
cytometry was directly associated with the particles which were bound onto the cells 
(blank control: Caco-2 cells only). A significant increase in the percentage of fluorescent 
labeled cells was detected after the cells were incubated with the lectin F-WGA 
conjugated particles, as compared with two other samples, i.e. fluorescent nanoparticles 
and particles without F-WGA modification. The different percentage of fluorescent cells 
between this experiment and the previous one (Figure 38) might be caused by the non-
uniform mixing of cells with particles during the incubation. The experiment was 
repeated twice and the percentage of fluorescent cells for the F-WGA conjugated NPs 
was 36% to 42% (three parallel samples for each independent experiment).  
 
79 
 
 
Figure 39. Function of lectin F-WGA as a targeting group as evaluated by flow 
cytometry. Caco-2 cells were incubated for 20 h with WGA or WGA conjugated 
CS/DEX (3 bilayers encapsulated nanoparticles (FWGA-NP)) at the WGA concentration 
1.5 µg/mL at 4 ºC (different batches from Figure 32). Cell fluorescence was caused by 
fluorescence of particles binding with the cells. NC – negative control, fluorescent 
nanoparticles; F-NP fluorescent nanoparticles encapsulated with 3 bilayers of CS/DEX 
and conjugated with PEG without WGA; WGA – F-WGA molecule only, positive 
control.  
 
6.3.5 Preliminary study on material biocompatibility  
PEG as a functional group was chemisorbed onto the nanoparticles’ surfaces so 
as to stabilize nanoparticles in suspension and increase the material biocompatibility. 
This molecule has been suggested to avoid adsorption of different proteins and increase 
the circulating time in the human body.
103
 This study was to test if these materials, 
including the polyelectrolytes, nanoparticles (polystyrene as the model core) and PEG, 
would be regarded to be safe to the human colon cells. As we know, paclitaxel was an 
anti-cancer drug, so it will show a therapeutic effect on the cells; therefore polystyrene 
nanoparticles were used temporarily here as the test core.  
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Figure 40. Cell viability as evaluated by the live/dead® cell viability assay (Invitrogen, 
USA) on Caco-2 cells after 20 h of incubation at 37ºC in direct contact with PEG 
conjugated CS/DEX encapsulated polystyrene nanoparticles (i.e. PS-CS/DEX-PEG). 
Cell viability data are reported as percentage ratio between viable cell number and total 
cell number. Control was used to incubate cells with polystyrene nanoparticles (PS) 
only. Negative control was CS/DEX encapsulated PS NPs before PEG conjugation (i.e. 
PS-CS/DEX). 
 
Figure 40 shows the results obtained from the particles’ direct contact with Caco-
2 cells, and the cell viability was tested using the live/dead
®
 cell viability assay. It was 
found that there was no significant difference of the cell viability among fluorescent 
particles, particles encapsulated with CS/DEX, and particles with CS/DEX layers 
conjugated with PEG after incubating them with cells. The data suggested that materials, 
i.e. particles, CS/DEX polyelectrolytes and PEG used in this drug delivery system did 
not release any substance that would significantly interfere with the cell viability for 20 
h.  
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6.4 Conclusion  
In this section, the morphology of different polyelectrolyte encapsulated PS NPs 
was first studied by TEM and SEM. Bio-polyelectrolytes chitosan and dextran have 
large glucose rings, so the LbL assembly showed rough surfaces as observed from the 
TEM images. LbL assembled particles modified with PEG were confirmed to be more 
stable than those without the PEG conjugation. The polyelectrolyte type and 
encapsulated layer number on the nanoparticles were found to be two factors that would 
influence the non specific adhesion of F-WGA.  F-WGA was confirmed as an effective 
targeting group after it was conjugated onto the LbL assembled nanoparticles. The 
fluorescence associated cells reached 60% when the F-WGA concentration on the 
particles’ surfaces was 15µg/mL. The preliminary biocompatibility study of the PEG 
modified nanoparticles showed: CS/DEX and PEG did not release any obvious toxic 
substances that would influence the cell viability.  
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7. SUMMARY AND CONCLUSIONS 
 
7.1 Summary  
This project mainly includes three parts: fabrication, encapsulation and 
modifications of paclitaxel based nanoparticles, synthesis, characterization and in vitro 
drug release study of the dextran based hydrogels, and in vitro evaluation of the 
modified nanoparticles with Caco-2 cells.  
PAX NPs were first fabricated at 100 nm by the modified emulsification 
evaporation method. Core-shell structured PAX NPs were prepared by encapsulating 
biomacromolecules chitosan and dextran using the LbL self-assembly technique. Surface 
modifications were then performed by conjugating with poly (ethylene glycol) and 
wheat germ agglutinin, so as to build a biocompatible and targeting drug delivery 
system. Adjustable release profiles could be obtained by tuning the layer number and 
buffer ionic strength.  
Two different dextran based pH sensitive and enzyme degradable hydrogels: 
dextran maleic acid (Dex-MA), and glycidyl methacrylated dextran (Dex-GMA) were 
synthesized for oral delivery of nanoparticles. Hydrogels of both kinds were stable in 
simulated gastric fluid, but prone to swelling and degrading in the presence or absence of 
enzyme dextranase in simulated intestinal fluid. The release profiles of nanoparticles 
were tuned by copolymerizing with other components under simulated human GI 
conditions. Two possible release mechanisms were discussed for Dex-MA and Dex-
GMA-co-AA hydrogels respectively: degradation controlled, and diffusion controlled. 
These two biodegradable hydrogels were considered as potential colon targeting vehicles 
for oral delivery of the drug nanoparticles.  
The stability test is important in developing a good nanoparticle based 
formulation. Particle instability may induce aggregation in suspension, which is 
undesirable for storage. The stability of LbL assembled fluorescent nanoparticles was 
investigated by measuring the zeta potential and the fluorescence intensity of the 
suspension after incubating the nanoparticles in SIF over certain time periods. In vitro 
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study of these WGA conjugated nanoparticles’ binding and uptake by Caco-2 cell line 
was performed at different WGA/nanoparticle concentrations. The efficacy of WGA as a 
targeting group to Caco-2 cells was studied by comparing particles with different 
surfaces, confirming that WGA was an effective group that promoted the particles’ 
binding capability to Caco-2 cells. Material biocompatibility was studied by incubating 
PEG conjugated nanoparticles with Caco-2 cells for 20 h at 37 ºC. 
 
7.2 Conclusions 
A nanoparticle based system consisting of a paclitaxel drug based core 
encapsulated with a nanometer thick biomacromolecule shell using the LbL assembly 
technique was successfully fabricated and characterized. The nanoshell provided specific 
sites on the surface which had been further modified with functional moieties, such as 
hydrophilic polymer PEG and ligand. This biocompatible drug delivery system, which 
combined passive accumulation with the active targeting moiety, could provide a 
potential alternative to more efficiently deliver hydrophobic drug to tumors. 
Two newly formed hydrogels developed in this project showed a good pH 
responsive swelling property. A much higher SR was observed for the Dex-GMA-co-
AA hydrogel at a composition of 40 mg/mL of Dex-GMA and 50 µL/mL of AA in the 
presence of enzyme dextranase. Adjustable release profiles could be obtained with the 
time window from 5 hr to 22 hr. The two Dex-MA-co-PEG and Dex-GMA-co-AA 
hydrogels, could promote dissolution of PAX NPs up to 5 days with 40 % of the PAX 
NPs released during the first 12 hr. It is suggested that both Dex-MA based and Dex-
GMA-co-AA hydrogels could be used as potential colon targeting vehicles for delivering 
nanoparticles orally.  
The key word of this colon targeting nanoparticle based drug delivery system is 
biocompatibility. Polysaccharides have been widely used in both building the 
nanoparticles’ polyelectrolyte shell and developing the new functional excipients for oral 
drug delivery. In the near future, it will become quite obvious that polysaccharide and 
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their derivatives will play a very important, if not the most important role, in developing 
novel formulations, especially functional excipients. 
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8. FUTURE WORK 
 
 
Further development of a potential nanoparticle based formulation is one of the 
next goals in this research. During the preparation of drug nanoparticles, different 
emulsifiers, instead of PVA, can be investigated to optimize the particle size and drug 
encapsulation efficiency. Other characterization tools such as differential scanning 
calorimetry (DSC) can be used to understand the physical state of the drug in the 
nanoparticles. In vitro kinetic models can be further explored to explain the drug 
nanoparticles’ releasing mechanism from the hydrogels. Using the microfluidic device to 
make the micro sized pH sensitive hydrogels is a potential way to obtain novel drug 
delivery vehicles for oral administration of nanoparticles.  
 
8.1 Development of paclitaxel nanoparticle based formulation  
8.1.1 Emulsifiers during the preparation of nanoparticles 
The enhanced activity of paclitaxel when incorporating it into nanoparticles can 
be explained: this system can act as a reservoir for paclitaxel, protecting the drug from 
epimerization and hydrolysis.
104
 Also it can provide sustained drug release and 
enhancement of its anti-tumor activity.
60
 Emulsifiers used in preparing these PAX NPs 
are critical to the particle encapsulation efficiency (EE) and particle size. A small 
amount of emulsifier would result in large particles, while a large amount of emulsifier 
would result in reduced drug EE. There is thus an optimal value of the emulsifier 
amount, at which nanoparticles of desired size and high EE can be obtained. 
The further study can start to explore natural emulsifiers, instead of just using the 
often-used surfactant PVA. PVA has the disadvantages of low emulsifying efficiency, 
low drug encapsulation efficiency, difficulty in removal and possibly being harmful to 
the human body.
105, 106
 D-α -tocopheryl polyethylene glycol 1000 succinate (vitamin E 
TPGS or TPGS) has recently been discovered as a good candidate in the paclitaxel based 
nanoparticle formulations.
107
 It was used in the paclitaxel-PLGA nanoparticle based drug 
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delivery system, which can be treated either as the surfactant stabilizer added in the 
water phase or as a matrix component material added in the oil phase in the process.
107-
108
 The drug encapsulation efficiency can be achieved as high as 100 %.
4
 
 
8.1.2 Further characterization of the nanoparticles 
In the process of manufacturing nanoparticles, several parameters are important, 
which can determine the physiochemical and pharmaceutical properties of the PAX NPs. 
These factors include the emulsifier used and its concentration in the aqueous phase, 
drug loading ratio, the oil to water phase ratio, the pH, homogenization speed and the 
temperature, etc.  
Various state-of-the-art techniques have been used in this research study to 
characterize the particles: dynamic light scattering (DLS) for size and size distribution, 
scanning electron microscopy (SEM), and transmission electron microscopy (TEM) for 
morphology, zeta-potential measurement for particle charge, X-ray photoelectron 
spectroscopy (XPS) for surface chemistry, and high performance liquid chromatography 
(HPLC) for drug EE and in vitro drug release studies.  
Other than the above techniques, the physical status of paclitaxel in the 
nanoparticles can also be analyzed by differential scanning calorimetry (DSC). This is to 
study the thermal characteristics of drug loaded nanoparticles.
107
 It was found that 
paclitaxel formulated in the nanoparticles was in an amorphous or disordered-crystalline 
phase of a molecular dispersion or a solid solution state in the polymer matrix.
109
  
For the LbL assembled nanoparticles, the XPS and zeta potential were used to 
confirm the success of building self-assembled polyelectrolyte layers on drug 
nanoparticles. The thickness of the polyelectrolyte layer built onto drug nanoparticles 
have been only estimated in this research from the TEM and SEM images. A more 
accurate measurement can be done by using fluorescent labeled polyelectrolyte, e.g. 
chitosan-FITC.
64
 The conformational state of a multilayer surface can be explored 
indirectly via the measurements of the surface roughness of dried films. For particles’ 
surfaces comprised of a significant population of loops and tails, upon drying, a 
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molecularly rough surface will be produced; smoother surfaces will be created if it is 
dominated by flat, trainlike segments.
20
 The layer thickness of weak polyelectrolytes 
may be greatly influenced by the pH in the buffer and the charge density. If the weak 
polyelectrolyte charge density is increased, the transition from thick adsorbed layers (~ 
8nm) to very thin adsorbed layers (0.4nm) can be observed, even over a very narrow pH 
range.
20
  
 
8.1.3 Development of the nanoparticle based formulation 
More than 40% of compounds have been identified as poorly soluble in water 
through a combinatorial screening program. The conventional method of formulating 
these drugs will not be appropriate. Nanoparticle based formulations for poorly soluble 
drugs have shown promising results regarding drug circulating time in the human body, 
bioavailability, drug exposure and feasibility of being postprocessed into other solid 
dosage forms.
110
  
The properties of nanoparticles which will determine their in-vitro and in-vivo 
performance include: particle size and size distribution, surface morphology and charge, 
surface chemistry, surface erosion and adhesion, drug diffusivity and encapsulation 
efficiency, drug stability and release kinetics, and the hemodynamic property of the 
nanoparticles.
61
 Stability of particles in the suspension is very important and it is ideal to 
maintain a good dispersion of these nanoparticles. An unstable nanoparticle suspension 
may change the above properties and thus the particles’ performance. Since this is the 
direct form obtained from the study, the stability of nanoparticles in suspension and 
storage of the suspension should be investigated first. A more stable formulation may be 
prepared using the freeze-thaw and then lyophilization/freeze- drying method.  
Freeze-drying has been considered as a good technique to improve the long-term 
stability of colloidal nanoparticles. The poor stability in an aqueous medium of these 
systems forms a real barrier against the clinical use of nanoparticles.
111
 The instability of 
nanoparticles may be caused by the polymer type used in preparing the nanoparticles, 
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pH in the aqueous dispersion, chemical stability of the entrapped drug, and storage 
temperature.
111
  
 
8.2 Release study 
In vitro release kinetic study is one important way to understand and possibly 
predict the drug release behavior in the human body. The release of poorly soluble drug 
from the nanoparticles in the aqueous suspension is dominated by self-erosion and 
dissolution of the matrix.
112
 Some factors may influence the release behavior of the drug 
from bare nanoparticles. It was found that based on different emulsifiers used, the 
release rates of paclitaxel from nanoparticles may be differed based on the ratio of 
hydrophobicity and hydrophilicity of the nanoparticle matrix.
4
  
Some factors that will influence the release rate of paclitaxel from bare 
nanoparticles are listed below: 
a. Surfactants that are used 
b. The property of the surfactants/emulsifier, more hydrophobic or hydrophilic 
c. The polymer/surfactant concentration 
d. The part where the surfactants are added. In the matrix formed materials or 
dissolved in the aqueous solution 
e. The organic/aqueous phase ratio, which influences the particle size. 
During the solvent extraction/evaporation process for preparing drug 
nanoparticles, natural emulsifiers, such as phospholipids, cholesterol, and vitamin E 
TPGS were applied to improve the drug encapsulation efficiency, desired drug release 
kinetics and higher cell uptake capacity.
4
 It was found that these natural emulsifiers have 
great advantages for the paclitaxel nanoparticle formulation over the traditional 
macromolecular emulsifiers, such as polyvinyl alcohol (PVA).
105
 The drug release 
profile can be controlled by using a specific emulsifier and optimizing its amount added. 
For example, with an increased amount of TPGS, the paclitaxel release rate increases 
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accordingly. This is because as more TPGS is used, the nanoparticle matrix becomes 
more hydrophilic.
4
 
The In vitro release of paclitaxel from different formulations can be performed in 
the presence and absence of human serum albumin by using a membrane dialysis system 
in phosphate buffered saline at 37 ºC and pH 7.0.
113
   
 
8.3 Dextran based pH sensitive microgels  
It was found that agarose droplets in the range of 50-110 µm can be produced by 
utilizing a microfluidic device with hydrodynamic flow focusing geometry.
114
 It has also 
been demonstrated that yeast cells can be encapsulated successfully into these agarose 
capsules.
114
 
 
 
 
 
 
 
 
Figure 41. a) Experimental setup for generating agarose gelled droplets. (Ice bath is to 
initiate the gelation of agarose.) b) Schematic of the microfluidic device with flow 
focusing geometry producing agarose droplets.
114
  Agarose solution is introduced into 
the center channel and two streams of oil are flowed into two side channels. The droplet 
size can be adjusted by changing the orifice size.   
 
Based on the above technology, dextran based microgels may also be produced 
by simply preparing the precursor as the aqueous phase and placing a UV lamp in the 
end to form the gels. The dextran based precursor Dex-GMA synthesized by our group 
was used first with the microfluidic device. Micro sized hydrogels were successfully 
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polymerized by UV irradiation. (Figure 42) The size of these microgels was 
homogeneous and could be further adjusted by changing the orifice size.   
 
 
Figure 42. Dextran-GMA based microgels prepared by microfluidic device. 
 
Fluorescent nanoparticles were added to the precursor solution and then 
encapsulated into the microgels. The encapsulation efficiency of nanoparticles into these 
microgels needs to be further studied. Some fluorescent nanoparticles might have been 
leaking out of the microgels during the centrifugation and washing process. There were 
still some fluorescent nanoparticles successfully trapped inside the microgels, as shown 
in the image obtained by fluorescence microscopy (Figure 43, right). 
 
 
Figure 43. Dextran-GMA-co-AA based microgels encapsulated with fluorescent 
nanoparticles. Bright field image (left); fluorescent image (right).  
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Figure 44. Size of dextran-GMA-co-AA microgels in different solvents. 
 
Interestingly, these dextran-GMA-co-AA based microgels showed different sizes 
in different solvents. Light mineral oil is the original solvent where the droplets gelled 
under UV irradiation, and the microgels showed around 50 µm in size, which was 
consistent with the orifice size.  Ethanol was followed to wash the microgels and remove 
the surfactant span 80 (5% w/w); the microgels shrunk in the ethanol. Different pH 
buffers were also used to test if these microgels were pH sensitive. The size of these 
dextran based microgels in SIF was bigger than that in SGF, indicating that they were 
pH sensitive. 
Further experiments can be performed to study the release of fluorescent 
nanoparticles and drug nanoparticles from these microgels. Possible problems may be: 
since these microgels will be transparent in the aqueous solution, separation of 
nanoparticles from these microgels will be difficult. An appropriate centrifugation speed 
may be applied to sediment the microgels, and the concentration of the fluorescent 
nanoparticles released in the supernatant may then be measured.   
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8.4 In vitro cell uptake study and in vivo animal studies 
The efficacy of the paclitaxel nanoparticle based system can be tested through 
incubating these particles with a colon adenocarcinoma cell line. Particles with and 
without drug encapsulation can be used, and the cell viability after the treatment with 
different nanoparticles can be analyzed by using the live/dead cell viability assay. The 
targeting group F-WGA can be conjugated onto the nanoparticles, and its efficiency can 
be measured by comparing the cell uptake capabilities.   
HT-29 is another typical human colon adenocarcinoma cell line, and can be 
maintained by serial passages in McCoy’s 5A medium supplemented with 10% fetal 
bovine serum (FBS), 2.2 g/L of sodium bicarbonate and 1% penicillin-streptomycin 
solution.
115
 These cells can be harvested and mixed with Caco-2 cells to test if F-WGA 
conjugated nanoparticles can also bind with and uptaken by these cells.  
NCM356 and NCM425 represent the first successful in vitro culture of human 
colonocytes derived from the normal mucosa. These cell lines are important resources 
for studying colon cancer and the physiology of intestinal cells.
116
 These colon normal 
cells can be mix-cultivated with the human colon adenocarcinoma cells, and the in vitro 
targeting functionality of nanoparticles with the cancer cells can be studied.  
In vivo animal testing can be further performed by using non-human vertebrate 
animals to understand the drug metabolic profile, material toxicology, and the drug 
delivery system.
117
 Metabolic tests aim to investigate the drug pharmacokinetics, i.e. 
how a drug can be absorbed, distributed, metabolized and excreted.
117
 The major 
obstacle for oral administration of poorly soluble drugs is low bioavailability and thus 
poor absorption by the body. Drug metabolic and efficacy tests between different 
formulations can provide valuable information to understand if the new formulation is 
superior on absorption. Since the colon targeting drug delivery system is pH dependent, 
and the small intestine shared similar pH with the colon, the small intestine transit time 
is therefore an important parameter for colon targeting drug delivery.
41
 One major 
limitation for this drug delivery system is the in vivo variation of the small intestinal 
transit time, which may result in undesirable releases of the bioactive in the small 
93 
 
intestine or the terminal part of the colon.
41
 The colon specific enzyme induced 
degradation of the hydrogels can possibly address the issue. Dextranase was found to 
indeed present in a human colonic fermentation model, and dextran based hydrogels had 
been investigated using the in vivo rats model. It was found in vivo that these dextran 
based pH sensitive hydrogels were degraded in the caecum of the rats, not in the 
stomach.
118
  Still, the goal during early development of an efficient drug delivery system 
is to obtain a formulation that is simple, flexible and fit for its intended purpose.
117
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APPENDIX A  
NANOPARTICLE BINDING WITH CELLS 
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1. Influence of  F-WGA concentration on nanoparticles binding with suspended 
Caco-2 cells 
1) Prepare the cells: cultivate for 5 days until 90% confluence. 18 mL 1.6*10^6 
cells/mL. 
2) Remove the old medium. Add PBS to wash the cells for 5 mins. Remove PBS, 
and add Trypsin/EDTA, incubate at 37 degree, 5% CO2 for 6 mins and check if 
cells are detached. Add fresh medium to deactivate the trypsin. 
3) Centrifuge the cells down for 7 mins, 125g. Resuspend in PBS and wash the cells 
twice. Split the cells into 15mL falcon tubes (3) with each tube 6 mL. Centrifuge 
and the cells are collected.  
4) Add the first tube with 6mL PBS and resuspend cells, this is negative control and 
used to calculate the autofluorescence. 2 ml in each well. 
5) Add the second with 6mL F-WGA (12.5 µg/mL, dissolved in sterile PBS, better 
if filtered).  Resuspend the cells well and split into 6 well plate with 2mL each 
well. 
6) Add the third with 6mL NP/CS/DEX-PEG-FWGA with 2mL each well.  
Resuspend the particles and cells well. Well mixed. 
7) Put in 4 degree, overnight, 20 hrs at 100 rpm shaking. 
8) Before measuring the fluorescence with flow cytometer, stop the shaker and let 
the cell stay still for at least 30 mins. Wash the cells with PBS at least twice and 
resuspend them in PBS. Sample should be highly concentrated, estimated cell 
number (5*10^6) cells/ml, volume for FACS analysis could be 500 µl-1000 µl. 
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 1 2 3 4 
F-WGA amount (mg) 0.3 0.3 0.6 0.6 
MAX Intensity  10^(-6) at 512nm 3.30 4.23 4.51 3.89 
Concentration (µg/mL) 91.2 99.3 102 96.3 
Average concentration of WGA conjugated onto PS nanoparticles: (97.1 ± 4.50) µg/mL 
 
 
 
Appendix Figure.1 Fluorescence intensity of F-WGA lectin and nanoparticle-F-WGA 
interacting with Caco-2 cells by flow cytometer (number of cells counted: 10,000) 
FL1-H: gate one, wavelength at 510/21 nm.Cell density: 1.6 × 10^6 cells/mL, totally 18 
mL, each 6 mL. Negative control: cells in PBS; positive control: F-WGA binding with 
cells; test sample: NP-WGA binding with cells.  (For cells interact with lectin at concen. 
13 µg/mL (the highest used)). 
 
4 ºC, 20hr, 100 rpm shaking overnight (20 hrs) 
Sample number 1 2 3 4 5 
F-WGA (µg/well) 26 15 5 1 0.2 
F-WGA (µg/mL) 13 7.5 2.5 0.5 0.1 
 
4*2=8 flasks T-75 collect all cells, totally 42 mL cells in PBS/F-WGA/NP-WGA. 
Purple-control cells 
Green-F-WGA with cells 
Pink-NP-WGA with cells 
Appendix Table.1 F-WGA conjugated PS nanoparticles (4 batches), fluorescent intensity 
and corresponding WGA concentration (µg/mL) 
104 
 
 
 
Appendix Figure.2 Histogram of different concentration of F-WGA conjugated 
nanoparticles binding with Caco-2 cells. Sample ID: purple- negative control; yellow: 
0.5 µg/mL WGA conjugated nanoparticles; blue: 2.5 µg/mL WGA conjugated 
nanoparticles; pink: 7.5 µg/mL WGA conjugated nanoparticles; dark blue green:13 
µg/mL WGA conjugated nanoparticles. 
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7.5 µg/mL WGA conjugated nanoparticles 
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4.5 µg/mL WGA conjugated nanoparticles 
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1.5 µg/mL WGA conjugated nanoparticles 
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0.5 µg/mL WGA conjugated nanoparticles 
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2. WGA as a targeting group conjugated onto LbL assembled nanoparticles 
 
Negative control: Caco-2 cells.  
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Positive control: LbL assembled fluorescent PS nanoparticles with PEG conjugation. 
Fluorescence comes from the PS nanoparticles.  
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Tagged nanoparticles: LbL assembled, PEG modified PS nanoparticles with F-WGA 
conjugation. Fluorescence comes from F-WGA. 
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